Skip to main content
PLOS Pathogens logoLink to PLOS Pathogens
. 2020 Jun 16;16(6):e1008621. doi: 10.1371/journal.ppat.1008621

CD11cHi monocyte-derived macrophages are a major cellular compartment infected by Mycobacterium tuberculosis

Jinhee Lee 1, Shayla Boyce 1, Jennifer Powers 1, Christina Baer 1, Christopher M Sassetti 1, Samuel M Behar 1,*
Editor: Marcel A Behr2
PMCID: PMC7319360  PMID: 32544188

Abstract

During tuberculosis, lung myeloid cells have two opposing roles: they are an intracellular niche occupied by Mycobacterium tuberculosis, and they restrict bacterial replication. Lung myeloid cells from mice infected with yellow-fluorescent protein expressing M. tuberculosis were analyzed by flow cytometry and transcriptional profiling to identify the cell types infected and their response to infection. CD14, CD38, and Abca1 were expressed more highly by infected alveolar macrophages and CD11cHi monocyte-derived cells compared to uninfected cells. CD14, CD38, and Abca1 “triple positive” (TP) cells had not only the highest infection rates and bacterial loads, but also a strong interferon-γ signature and nitric oxide synthetase-2 production indicating recognition by T cells. Despite evidence of T cell recognition and appropriate activation, these TP macrophages are a cellular compartment occupied by M. tuberculosis long-term. Defining the niche where M. tuberculosis resists elimination promises to provide insight into why inducing sterilizing immunity is a formidable challenge.

Author summary

The initial cell type infected by Mycobacterium tuberculosis is generally acknowledged to be the alveolar macrophage; subsequently, the bacilli spread to other types of myeloid cells, and other macrophages, dendritic cells, and neutrophils become infected. These infected cells are recognized by M. tuberculosis-specific T cells that restrict bacterial growth. However, M. tuberculosis resists elimination and persists as a chronic infection. How M. tuberculosis persists despite a robust immune response is a critical question. To identify the cell types where M. tuberculosis persists, we combined a comprehensive flow cytometry panel with yellow-fluorescent protein-expressing M. tuberculosis to identify the cell types infected and their response to infection. The strong interferon-γ signature of infected cells was consistent with ongoing T cell recognition in the lung. Importantly, we defined a population of myeloid cells, primarily CD11cHi monocyte-derived cells, which expressed high levels of CD14, CD38, and Abca1, and had the highest infection rates and bacterial loads. Despite evidence of T cell recognition and appropriate activation, these CD11cHi macrophages remain infected by M. tuberculosis long-term. Defining this niche should help answer why M. tuberculosis resists elimination from activated macrophages even in the face of T cell immunity.

Introduction

Our respiratory system is in direct contact with the environment and the lung’s large surface area is patrolled by the immune system to eliminate inhaled particles and microbes. Leukocytes, which reside in lung parenchyma and circulate through its extensive vasculature, play crucial roles in combating viruses, bacteria, fungi and parasites. To understand the pathogenesis of these and other diseases, great effort has gone into characterizing the lung’s resident myeloid cells [1, 2]. During inflammation, resident cells change phenotype, function, and location, while other cells are recruited and marginate from the blood to enter lung tissue [3, 4]. Myeloid cells have enormous plasticity and their activation states and functions are shaped by exogenous signals to which they are exposed (e.g., bacterial products, cytokines, hypoxia, cigarette smoke) [58]. Thus, the same cell type can be pro-inflammatory and resist infection, or anti-inflammatory and help resolve inflammation and remodel injured tissue.

The bacterium Mycobacterium tuberculosis (Mtb) causes the human disease tuberculosis (TB). Mtb infects alveolar macrophages (AM) and replicates intracellularly [9]. However, Mtb infects other myeloid lineage cells, including other types of macrophages, dendritic cells (DC), and neutrophils [1012]. AM appear to poorly control intracellular Mtb growth, while monocyte-derived cells (MDC), such as interstitial macrophages (IM), more efficiently inhibit bacterial growth [13, 14]. Nevertheless, Mtb resists elimination and persists as a chronic infection. The inability of the myeloid cells to contain the infection stems in part from the propensity of infected cells to die a necrotic death leading to bacterial dispersal, and infection of other cells [15, 16]. Ultimately, bacterial growth plateaus only when T cells are recruited to the lung, where they recognize and activate infected cells [1719]. Indeed, impairment of cell mediated immunity or loss of T cell function increases the risk of developing active TB [20]. However, even in the presence of T cells, viable bacteria persist in animal models of primary TB. Why T cells are unable to mediate sterilizing immunity is unclear although T cell dysfunction and immune evasion are likely contributors.

The difficulty in distinguishing different types of myeloid cells is one barrier to unraveling mechanisms of immune evasion during TB. The inflammatory milieu during infection promotes recruitment, activation and differentiation of myeloid cells in the lung [21]. We developed a gating strategy that unambiguously classifies lung myeloid cells and made use of a strain of H37Rv that constitutively expresses a super-folding yellow fluorescent protein (YFP), to track and sort infected cells. We determined the gene expression profiles of uninfected and infected cells belonging to the three major non-PMN myeloid cell populations. Twenty-five genes were upregulated by all three cell populations and we validated that CD14, CD38, and Abca1 were co-expressed by the majority to infected cells in the lung. These markers were induced by a combination of Mtb and γ-interferon, a product of the T cell response. Here we discovered that these markers identify a subset of CD11chi monocyte-derived cells (CD11chi MDC) that is highly infected and defines a cell population where Mtb persists in the lung.

Results

Monocyte-derived macrophages increase in the lung parenchyma during Mtb infection

During the past two decades, there have been major advances in our understanding of the origin and differentiation of myeloid cells [2, 5, 9, 13, 2226]. However, in the lungs of infected mice, standard classifications can be difficult to implement because of the diverse activation states of different cell types. To overcome this uncertainty, we developed the following flow cytometric strategy to more precisely categorize lung myeloid cells. We first excluded debris, doublets, and dead cells (S1 Fig). CD45+ leukocytes were distinguished from non-hematopoietic cells, a “dump” channel was used to exclude lymphoid cells (T, B, and NK cells), and neutrophils (PMNs) were identified by Ly6gHi expression (S1 and S2 Figs). AM were identified by their SiglecFHiCD11cHi phenotype and eosinophils by their intermediate SiglecF expression and lack of CD11c. In uninfected lung, two subsets of conventional CD11cHi DC were identified based on their differential expression of CD103 and CD11b. Additionally, CD11bHi cells expressing low or intermediate levels of CD11c were identified as Ly6cHi or Ly6cLo monocyte/macrophages. Pulmonary DC can be identified by their co-expression of CD11c and MHCII in uninfected mice, as only low MHCII levels are expressed by AM (Fig 1A). Similarly, low CD11b levels are expressed by AM (Fig 1B). However, MHCII and CD11b are both significantly upregulated by AM during Mtb infection (Fig 1A and 1B). Importantly, CD11c and SiglecF unambiguously identify AM, even during Mtb infection, and avoids their misclassification as pulmonary DC or recruited myeloid cells (S3 Fig).

Fig 1. Expression of MHCII and CD11b are increased by AM during Mtb infection.

Fig 1

A, B. MHCII is significantly upregulated on AM after Mtb infection. C57BL/6 mice were infected by aerosol with ~100 Rv.YFP. After 4 weeks, lung myeloid cells collected from infected mice were compared with those from uninfected mice for the expression of MHCII (A) and CD11b (B) on each myeloid cell subset. C, D. Each myeloid subset populates a distinct anatomical site. Six weeks after infection, mice were injected i.v. with fluorophore-labelled anti-CD45 mAb 3 min before euthanasia. (C, D) “Control” denotes lung cells from an uninjected mouse. PBMC was used to measure the efficiency of vascular staining. Nearly 50% of lung cells were in the vasculature. Each myeloid cell subset was analyzed for its staining with anti-CD45 mAb. E. Myeloid populations selectively expand after infection. Total lung cells were obtained from uninfected mice or mice infected with Rv.YFP for 3 weeks. 3 wpi, the total number of cells was increased in CD11cHi MDC, RM/mono, monocytes, and PMN after infection, but the number of AM, CD103 DC, and EOS remained unchanged. Each value represents the average of 5 mice. F, G. The number and relative abundance of RM/mono, monocytes, PMNs, and CD11cHi MDC, peaked 1 month after infection and then declined. Each value represents the average of 5 mice. H: IMs constitute a small fraction of the lung myeloid cells, after 3 weeks post aerosol Mtb infection. The gating scheme used by Huang et al. was used to identify IM (defined as CD64+MertK+SiglecF- non-PMN myeloid cells). The numbers refer to the percentage of each cell population among non-PMN myeloid cells. I. CD11cHi MDC overlap with IM. Using our gating scheme, we define the percentage of each cell population among non-PMN myeloid cells (left, blue numbers). The expression of CD64 and MertK is determined for each major cell population, and the percentage of CD64+MertK+ cells is indicated by the black numbers. J. AM, IM, CD11cHi MDC, and Mono were analyzed for the expression of CX3CR1 and Ly6C, markers for monocyte-derived cells. These results are representative of 5 (A-D), 2 (E), 2 (F, G), 2 (H-J) experiments. The SD for Fig 1D, 1H, 1I and 1J are not shown for clarity, but were generally <10% of the mean. PMN, neutrophils; EOS or eosin, eosinophils; Mono, monocytes; RM, recruited macrophages, AM, alveolar macrophages; CD103DC, cDC1; CD11bDC, cDC2; CD11cHi MDC, CD11cHi monocyte-derived cells. **, p<0.01, ***, p<0.001, p<0.0001, by a two-way ANOVA.

We distinguished cells in the lung parenchyma (i.e., tissue resident) from those in the vasculature by intravenously administering anti-CD45 mAb [27] (Fig 1C). In uninfected mice, AM, CD103DC, and most CD11bDC, were tissue resident, while the majority of monocytes, eosinophils and PMNs were circulating (Fig 1D). The intravascular location of the Ly6cLo population makes it likely that these cells are nonclassical monocytes [1].

After Mtb infection, the absolute number and relative proportion of these populations change and within 3–4 weeks post infection (wpi), there was a significant increase in the total number of myeloid cells in the Mtb-infected lung [10, 21, 28] (Fig 1E). Although the relative abundance of AM declined, they were detected for months following infection (Fig 1F and 1G). The large increase in lung CD11b+CD11c+SiglecF- myeloid cells after Mtb infection, and their presence in the circulation as well as in the parenchyma led us to conclude that this cell population is heterogenous and includes both CD11bDC and recruited myeloid cells. As we have previously shown that CD11b+CD11c+MHCIIHi myeloid cells in the lungs of Mtb infected mice can be derived from recruited monocytes [21], we favor the idea that most of the CD11b+CD11c+SiglecF- lung cells are monocyte-derived cells (MDC), but may include resident CD11bDC. Indeed, Norris and Ernst find that there is a large recruitment of monocytes to the lung parenchyma where they proliferate and differentiate into lung resident myeloid cells, including CD11bDC [27]. Based on data presented below, we believe that both the majority of the CD11b+CD11c+MHCIIHi cells are MDC and are more similar to macrophages than DC [13, 21, 27]. Hereafter, we refer to these cells as CD11cHi MDC. The Ly6cLo cells that entered the parenchyma are recruited macrophages (RM), another type of monocyte-derived macrophage [1, 2, 24]. Importantly, RM, monocytes, PMN and CD11cHi MDC were the most abundant myeloid cell types in the lung following Mtb infection (Fig 1F and 1G).

Huang et al identified a population of lung myeloid cells after high-dose intranasal Mtb infection that resembled the population we are calling CD11cHi MDC [13]. These cells were CD11bHiCD11cintMHCIIHi and based on their co-expression of CD64 and MerTK, and lack of SiglecF, these cells were called interstitial macrophages (IM) [2]. To determine whether CD11cHi MDC were similar to IM, we analyzed lung myeloid cells three weeks after low-dose aerosol Mtb infection using a modified flow panel. The majority CD64+Mertk+ macrophages were AM (~85%), and only 2% of the total myeloid cells in the lungs were IM based on the Huang’s definition (Fig 1H). The reciprocal analysis showed that while all AM were CD64+MerTK+, only ~10% of CD11cHi MDC were MerTK+ (Fig 1I). The monocyte markers Ly6c and CX3CR1, which are often retained by MDC, were expressed by CD11cHi MDC, CD64+MerTK+ cells (“IM”), and monocytes, but not AM (Fig 1J). The heterogeneity in MerTK expression among CD11b+CD11cHiMHCIIHi cells may reflect distinct cell populations (i.e., DC vs macrophage), or asynchronous recruitment, differentiation or activation. Thus, monocyte-derived macrophages increase in the lung following Mtb infection.

CD11cHi MDC are highly infected

Prior studies identified Mtb-infected cells using CD11b and CD11c, focused on one or two cell types, or looked at early time points [10, 13, 21, 28, 29]. We used H37Rv expressing a bright sfYFP (Rv.YFP) [30]. Analysis by image flow cytometry showed that YFP+ cells could be clearly differentiated from the uninfected population. To determine if the MFI of YFP correlated with bacterial burden, we sorted YFPlo, YFPint, or YFPHi AM. Imaging of YFP+ cells showed the YFP signal was derived from intracellular fluorescent bacilli. The YFP MFI was proportional to the number of bacilli per cell, showing that MFI could be used as a surrogate for bacterial number (Fig 2A and 2B).

Fig 2. Infected myeloid cells can be tracked using Rv.YFP.

Fig 2

A, B. To correlate bacterial load and MFI, C57BL/6 mice were infected i.t. with a high dose (1 x 105 per animal) of Rv.YFP. Alveolar macrophages were sorted into YFP-ve, YFPlow, YFPint, and YFPHi using a cell sorter (A), and each bin of sorted cells was analyzed by fluorescence microscopy (B). The images were captured by confocal microscopy using a 60x objective. C, D, E. At 3 wpi, total lung cells from infected mice were collected, and each myeloid subset was analyzed to determine the frequency of YFP-positive cells (C). Results from four independent mice summarized (D). From the same experiment, the YFP+ cells were gated and then the frequency of the different myeloid cells present was determined (E). Each pie slice represents the average of 4 mice. These data are representative of 3 experiments. ****, p<0.0001 by 1-way ANOVA compared to eosinophils.

Following infection with Rv.YFP, we determined the fraction of lung cells that were infected. At 3 wpi, Rv.YFP+ cells were detected among all seven populations (Fig 2C). AM, PMNs, RM, and CD103DC, were infected at a similarly low rate (Fig 2C). Remarkably, CD11cHi MDC were infected at ~20-fold higher rate than AM and other cell types (Fig 2D). Thus, even though there are fewer CD11cHi MDC than PMNs in lung tissue, they become a major intracellular reservoir for Mtb (Fig 2E).

Infected AM have a transcriptional signature signifying interaction with T cells

To assess how different cells respond to intracellular Mtb infection, we transcriptionally profiled infected and uninfected cells from the lungs of Mtb-infected mice 3 wpi. We first analyzed AM as they are the cell type initially infected [9]. Following Rv.YFP infection, YFPpos and YFPneg AM were flow sorted from the lungs of infected mice, as well as AM from uninfected mice (AMUninf). Transcriptional changes were detected in 2,150 genes expressed by YFPpos AM, and 2,392 genes expressed by YFPneg AM, compared to AMUninf, based on an FDR <0.05 and a fold-change ±2-fold (Fig 3A). Of the 3,051 genes which changed after Mtb infection, there was an overlap of 1,492 genes, with similar numbers of genes being upregulated or downregulated by YFPpos or YFPneg AM compared to AMUninf (Fig 3B and 3C). These data show that pulmonary Mtb infection affects gene transcription in both uninfected and infected AM, demonstrating how profoundly the inflammatory milieu affects bystander cells.

Fig 3. Infected AM display the unique transcriptional signature.

Fig 3

A. Differentially regulated genes (DRGs) between infected (“YFPpos”) or uninfected (“YFPneg”) AM from Mtb-infected lungs vs. uninfected macrophages from naïve mice (“N”, e.g., YFPpos/N or YFPneg/N) were determined using criteria of [FC]>2 and an FDR<0.05. The 3051 DRGs were clustered and a heat map generated. Each column represents each animal. B. Distribution of genes specifically up or down regulated in AM of Mtb-infected mice vs. AMs of naïve mice were depicted. C. Upregulated genes and downregulated genes were separately analyzed between AM of Mtb-infected mice and AM of uninfected mice. D. 370 genes that were differentially expressed between YFPpos or YFPneg AM from infected mice were clustered, and a heat map generated. E. The results of the GSEA analysis of the 370 DRGs.

To identify transcriptional changes that are specific to Mtb-infected AM, we next compared YFPpos AM vs. YFPneg AM. A total of 518 genes were differentially expressed by greater than 2-fold (FDR<0.05), and 370 of these were known genes (Fig 3D). GSEA analysis of the differentially regulated genes (DRG) in YFPpos versus YFPneg AM revealed that several functional pathways were regulated in Mtb-infected AM (Fig 3E). Based on the normalized gene enrichment scores (NES), Mtb-infected AM were activated by IFNγ, TNF and TLR ligands, while cell division and proliferation were inhibited. Based on the significant enrichment of IFNγ regulated transcripts, we infer that that T cells are specifically interacting with Mtb-infected AM.

The gene signature of CD11cHi MDC is similar to macrophages and monocytes

We next compared the transcriptional profile of YFPpos AM, YFPpos CD11cHi MDC, and YFPpos RM to the transcriptional profile of purified cell types from the lungs of uninfected mice (immgen.org) and to the gene expression signatures previously established for DC, macrophages, and monocytes (Figs 4 and S4) [31, 32]. Mtb-infected AM had a gene expression profile similar to AM (S4A Fig). The YFPpos CD11cHi MDC, which we had originally predicted to be DC, had a gene expression pattern more consistent with macrophages and distinct from that of AM and DC (Figs 4A and S4A). YFPpos RM had a gene signature that overlapped with monocytes and macrophages. These gene signatures were quantitated by determining the relative gene expression for each gene in the signature and comparing the seven populations we analyzed to 43 myeloid cell populations from ImmGen.org (Figs 4B and S4B). Although a general trend was evident, there were some discrepancies even among the ImmGen subsets. For example, CD11b+ lung macrophages (non-AM) appeared to be more DC-like (Fig 4B). Therefore, we derived a 21 gene signature (S4B and S4C Fig) that distinguishes DC from macrophages and used this signature to perform a Pearson correlation analysis was performed for all cell populations. There was a high degree of similarity between the population of YFPpos AM, YFPpos CD11cHi MDC, and YFPpos RM with normal populations of macrophages. These data are consistent with their derivation from monocytes and support defining these cells as CD11cHi MDC [13, 21, 27].

Fig 4. The transcriptional signature of YFPpos CD11cHi MDC is closely aligned with macrophages and monocytes.

Fig 4

A. Using well-described transcriptional gene signatures for DC [32] or macrophages [31], YFPpos AM, CD11cHi MDC, and RM were compared to well-defined lung myeloid cell populations from uninfected mice (data from www.Immgen.org) using a heat map with global normalization. B. To quantify the macrophage and DC gene signatures, the log2[specific gene expression / average total gene expression] was determined for 43 myeloid unique ImmGen myeloid cell populations and the seven populations we analyzed, grouped by cell type or “Mtb lung data”, which refers to data derived from this study. Red bar, median. pDC, plasmacytoid DC. Blue, ImmGen lung populations; open black, AM from uninfected mice; open red; YFPneg cells; closed red, YFPpos cells. Not that the ImmGen data and our data obtained with different Affymetrix chips. C. Using a gene signature that distinguishes ImmGen DC from macrophages (see S4 Fig), a Pearson correlation analysis was performed for all the cell populations. “*” indicates YFPpos populations.

The transcriptional program of Mtb-infected cells is affected by both pro- and anti-inflammatory cytokines

Gene expression by YFPpos vs. YFPneg CD11cHi MDC, or YFPpos vs. YFPneg RM, were compared and DRGs were identified based on an FDR <0.05 and a ±2-fold-change. We identified 231 DRGs among CD11cHi MDC and 424 DRGs in RM. The expression of the DRGs in YFPpos vs. YFPneg AM, CD11cHi MDC, and RM is presented graphically (Fig 5A, 5B and 5C). DRGs included cytokines (IL-1α, IL-1β), mediators of microbial immunity (NOS2), and regulators of lipid and eicosanoid synthesis (Ptgs2, Alox5, PPARγ, Fabp1, Abca1). Using the Ingenuity pathway analysis platform, LPS/MyD88, IFNγ, TNF, and IL-1β, were identified as activating upstream regulators that likely explain the transcriptional differences between YFPpos vs. YFPneg cells (Fig 5D). Importantly, most of these upstream regulators were products of activated CD4 or CD8 T cells (e.g., IFNγ, TNF, GM-CSF, and IL-2), or reflected innate microbial sensing (e.g., MyD88, IL-6, TNF, IL-1β), indicating that T cell recognition of Mtb-infected cells may be driving these gene signatures. In addition, there were signals of inhibitory cytokines including IL-4, IL-10 and TGFβ, which could modify the degree of inflammation and even impair anti-microbial immunity.

Fig 5. Transcriptional analysis of infected AM, CD11cHi MDC, and RM.

Fig 5

A, B, C. Using an FDR <0.05 and a fold-change >[2], we detected 370, 231, and 424 DRGs, between YFPpos and YFPneg cells in AM (A), CD11cHiMDC (B), and RM (C) from infected mice, respectively. For each of these cell types, the log2 expression differences between YFPpos and YFPneg cells is plotted. The line of identity is the dashed line; the solid line represents ±2, and the dotted line is ±4-fold difference. Red dots identify genes that were differentially regulated in all three cell types. Green dots identify other genes of interest. The identities of some genes are annotated. D. Ingenuity pathway analysis (IPA) predicted upstream signals for each cell type based on the DRGs. Each bar represents the -log10(p value). E, F, G. IPA predicted canonical pathways based on DRGs. Pathways predicted to be upregulated are shaded using warm colors; pathways predicted to be downregulated are shaded with cool colors. The bars indicate the log10 p values; the line indicates the fraction of genes from each pathway that were identified as DRGs. H. Top pathways predicted by GSEA for each cell type. Bars, normalized enrichment score (NES). FDR<0.05 (solid bars); FDR>0.05 (open bars).

To perform pathway analysis, sets of DRGs with an FDR <0.05 were assembled. These sets contained 288, 464, and 624 genes for AM, CD11cHi MDC, and RM, respectively. The top pathway predicted to be activated in infected AM by Ingenuity was “neuroinflammation,” which includes NOS2, COX2, VCAM1, SLC1A2, IL-1β, among others (Fig 5E). Cholesterol biosynthesis and LXR/RXR pathways were predicted to be inhibited in infected AM. Although other molecules including NOS2 and IL-1α were highly expressed by YFPpos CD11cHi MDC, the predicted regulated pathways differed from AM (Fig 5F). The neuro-inflammation pathway was predicted to be downregulated in infected CD11cHi MDC, and the chief differences were driven by downregulation of CXCR1, TLR9, and FOS expression. Interestingly, the IFNγ signaling pathway was not significantly activated in CD11cHi MDC, despite changes in the expression of interferon regulated genes (e.g., SPP1, NOS2, IL1A). These data could reflect IFNγ acting on both uninfected and infected CD11cHi MDC or inhibition of IFNγ signaling in a subset of MDC. The complement system, pattern recognition receptor, and inhibition of matrix metalloproteinases pathways were predicted to be activated in Mtb-infected RM (Fig 5G). GSEA analysis showed that infected AM, CD11cHi MDC, and RM had similar transcription responses, but the responses of CD11cHi MDC and RM were more similar to each other (Fig 5H).

Identification of myeloid cells that are highly enriched for Mtb-infection

We identified a core set of 25 genes that was upregulated by all infected cell types >2-fold with an FDR <0.05 (Fig 6A). These genes were all upregulated in YFPpos vs. YFPneg AM, CD11cHi MDC, and RM (Fig 6B). Prominent among this gene set was NOS2, which is required for the synthesis of nitric oxide (NO), an antimicrobial molecule that also has anti-inflammatory effects [33, 34]. Two c-type lectins, Clec4d and Clec4e, were significantly upregulated in all three cell types. Clec4d (MCL) and Clec4e (Mincle) bind to Mtb ligands, (i.e., trehalose 6,6'-dimycolate, a.k.a cord factor) and are upregulated on myeloid cells after infection with other pathogens [35, 36]. To determine whether the corresponding proteins were regulated following Mtb infection, we used flow cytometry. We initially focused on CD38, CD14, ABCA1 and podoplanin, as their transcripts were highly upregulated by Mtb-infected AM, CD11cHi MDC, and RM compared to uninfected cells. As our gene expression studies were limited to non-PMN myeloid cell types, we excluded PMNs from our flow cytometric analysis.

Fig 6. 25 genes are upregulated genes in infected AM, CD11cHi MDC, and RM.

Fig 6

A. The distribution of the 724 genes that are upregulated in YFPpos or YFPneg AM, YFPpos or YFPneg CD11cHi MDC, or YFPpos or YFPneg RM. B. The expression levels of the 25 shared genes in YFPpos vs. YFPneg AM, CD11cHi MDC, or RM. For AM, data from uninfected AM obtained from uninfected mice, is also shown.

In uninfected mice, fewer than 0.5% of lung non-PMN myeloid cells expressed CD38, CD14, and ABCA1 (Fig 7A, top row). In contrast, 3 weeks after infection, all three markers were present in various combinations on cells from the lungs of infected mice, and 10% of cells expressed high levels of all three markers (Fig 7A, bottom row, Q2, population “D”). Podoplanin was also enriched among Mtb-infected cells (S5 Fig). Importantly, most of the CD38+CD14+ABCA1+ myeloid cells (hereafter referred to as ‘triple-positive’ or ‘TP’) were CD11cHi MDC (Fig 7B). Analysis of lung cells obtained from Rv.YFP-infected mice showed that CD38, CD14, and ABCA1 were more frequently co-expressed by Mtb-infected cells than by uninfected cells, as predicted by our transcriptional analysis (Fig 7C). Thus, 30–40% of the TP myeloid cells in the lungs of Mtb-infected mice were infected (i.e., YFPpos), while only 1–2% of the non-TP cells were YFPpos (Fig 7C).

Fig 7. CD38+/CD14+/ABCA1+ (‘TP’ cells) myeloid cells are highly Mtb-infected.

Fig 7

A. The expression of CD38, CD14, and ABCA1 by non-PMN myeloid cells from the lungs of B6 mice, 3 wpi. Quadrants are defined as follows: Q1, CD38+CD14-ve; Q2, CD38+CD14+; Q3, CD38-veCD14+; and Q4, CD38-veCD14-ve. Each quadrant was then further divided into Abca1 negative and positive cells. This Boolean gating based on CD38, CD14, and ABCA1 expression defines 8 populations (labelled ‘A’ through ‘H’). B. The frequency of TP cells in each myeloid cell subsets. Each point represents one individual subject. C. CD38+CD14+ABCA1+ (‘TP’ cells) are enriched among YFP+ cells. Quadrants, based on CD38 and CD14 staining, were analyzed for YFP and ABCA1 expression. The highest frequency of YFP+ cells is found in CD38+CD14+ABCA1+ cells. D. For each of the gated cells populations labelled in Fig 7A as A through H, we determined: (1) the percentage of total myeloid cells in each gate; (2) the frequency of cells in each gate that are infected with Rv.YFP; (3) the contribution that each population makes to the total number of infected cells; and, (4) the MFI of the YFP+ cells in each gate. These data are representative of five independent experiments. Empty bars, ‘TN’ cells; red bars, ‘TP’ cells. Statistics, one-way ANOVA compared to ‘TN’ cells. Error bars, SD. *, p<0.05; **, <0.01, ***, <0.001, ****, <0.0001.

We next systematically analyzed the expression of CD38, CD14, and ABCA1 among lung myeloid cells, after excluding PMNs, using a Boolean gating strategy. The four quadrants defined by CD38 and CD14 expression were analyzed for ABCA1, and the frequency of infected cells was determined for each of the resulting eight populations (i.e., A-H, see Fig 7A) (Fig 7D). The CD38+/CD14+ cells were the main cell population that expressed high levels of ABCA1 after infection (Fig 7A). The triple negative cell (population G (white bar), ‘TN’) were the largest subset accounting for ~55% of all myeloid cells; the other seven populations accounted for between 5–10% of myeloid cells (Fig 7D). These TN cells had a low rate of infection, especially in contrast to the TP cells (population D (red bar), of which nearly 40% were Rv.YFP+ (Fig 7D). Thus, although they only account for ~10% of the lung myeloid cells, the TP cells account for ~60% of the non-PMN infected cells (Fig 7D). Furthermore, the MFI of Rv.YFP was significantly higher in the TP cells than in other the cell populations (Fig 7D). Since we have established that the MFI of Rv.YFP correlates with the number of bacteria/cell (Fig 2A and 2B), these data indicate that the TP cells have more bacteria per cell. Thus, CD38, CD14, and ABCA1 define a population of myeloid cells that harbor most of the bacteria in the lungs of infected mice.

Infected ‘TP’ cells are activated

Mtb-infected AM, CD11cHi MDC, and RM had an activated transcriptional signature consistent with upstream regulators IFNγ, TNF and TLR signaling (Figs 3, 5 and 6). The NOS2 transcript was highly upregulated in all three infected cell subsets (Figs 3, 5 and 6). We confirmed that NOS2 protein was induced in all three subsets (Fig 8A), roughly in proportion to their bacterial load (Fig 2D). To confirm that Mtb-infected cells expressed NOS2 protein, lung myeloid cells were analyzed after Rv.YFP infection. NOS2 was detected in 67% of Mtb-infected cells compared to only 4% of uninfected cells (Fig 8B). NOS2 has previously been shown to be expressed by Mtb-infected cells [9, 13, 37]. Similarly, intracellular pro-IL-1β protein was detected in 30% of YFP+ cells in the lung (Fig 8B). Having found that infected cells are more likely to have a ‘TP’ phenotype, we assessed the phenotype of NOS2-expressing cells: 90% co-expressed CD14 and CD38 (Fig 8C). Conversely, CD38+CD14+ cells were highly enriched for NOS2 and IL-1β producing cells (Fig 8D). Finally, using Boolean gating to define eight populations of cells (i.e., populations A-H from Fig 7A), we find that TP cells had the highest frequency of NOS2 producers as well as the highest expression of NOS2 (Fig 8E). Thus, not only are lung myeloid cells expressing CD38, CD14, and ABCA1, more likely to be infected following Mtb infection, but they are also more likely to be expressing NOS2 and IL-1, which are associated with the anti-mycobacterial response.

Fig 8. TP cells are NOS2-producing.

Fig 8

A. The frequency of NOS2+ cells among CD11cHi MDC, AM and RM. B. Most Mtb-infected cells (Rv.YFP+) produce NOS2 and many produce IL-1β. C. NOS2 was produced nearly exclusively by CD14/CD38 double positive cells. The expression of CD14 and CD38 by NOS2-ve (R1) and NOS2+ (R2) cells was determined by flow cytometry. D. CD38+/CD14+ cells are highly enriched in cells producing NOS2 and IL-1β. CD14/CD38 double positive cells (Q2), or double negative cells (Q4) were analyzed for intracellular NOS2 and IL-1β expression. E. TP cells produce the highest amount of NOS2. For each of the cell populations expressing various combinations of CD38, CD14 and ABCA1 (A-H, defined by Boolean gating, see Fig 6), we determined the: (1) percentage of cells that produce NOS2; and, (2) the MFI of NOS2 expression. Empty bars, ‘TN’ cells; red bars, ‘TP’ cells. The plots were gated on non-PMN myeloid cells and are representative of three independent experiments. Statistics, one-way ANOVA compared to ‘TN’ cells. Error bars, SD. *, p<0.05; **, <0.01, ***, <0.001, ****, <0.0001.

IFNγ drives TP cells to express CD38

We hypothesized TP cells are highly infected because they are more phagocytic than other subsets. To determine whether lung TP cells are more phagocytic, we obtained lung cells from mice infected with Rv.YFP 3 wpi, and measured their uptake of Rv.mCherry or yellow-orange (YO)-beads. As expected, Rv.YFP was preferentially found in the CD38+CD14+ cells (Fig 9A, top row). By excluding the Rv.YFP infected cells, the phagocytic activity of the uninfected lung cells could be measured. Except for the CD38+CD14- cells, which were poorly phagocytic, the YO-beads were also evenly distributed among cells that differed in their expression of CD14 and CD38 (Fig 9A, bottom row). The infection of myeloid cells in vitro by Rv.mCherry was independent of CD14 and CD38 expression (Fig 9A, middle row). These results indicate that a difference in phagocytosis cannot explain why TP cells are more infected than other myeloid cells.

Fig 9. TP cell phagocytosis and IFNγ responsiveness.

Fig 9

A. Lung TP myeloid cells are not more phagocytic or likely to become infected by Mtb. Four weeks after infection with Rv.YFP, single cell suspensions from the lung were obtained and infected in vitro with Rv.mCherry (MOI 5, 2.5 h). Cells were also incubated with YO-beads to measure phagocytosis. Top row, Distribution of Rv.YFP among CD14/CD38-expressing myeloid cells. After excluding the Rv.YFP+ cells by gating, the Rv.YFP-ve cells were analyzed for their uptake of Rv.mCherry (middle row), or phagocytosis of YO-beads (bottom row). B. IFNγ promotes CD38 and CD14 expression by myeloid cells. BMDC and BMDC were infected with Rv.YFP at an MOI of 0.2 in the presence or absence of IFNγ for 1, 2, or 5 days, and the expression of CD28, CD14, and ABCA1 were determined. C. IFNγ promotes TP cell generation in vivo. IFNγ KO or WT mice were infected with Rv.YFP and on day 25, non-PMN myeloid cells were analyzed for the expression of CD14, CD38, and Abca1. These data are from individually analyzed mice (WT, n = 3; IFNγ KO, n = 3).

Having identified that TP cells as frequently infected by Mtb, we asked whether host or microbial factors drive their generation. BMDC express CD14 and moderate amounts of CD38, while BMDM express CD14 but little CD38. A clear synergistic effect was observed when Mtb-infected cells were treated with IFNγ, an effect that was most pronounced for CD38 expression by BMDC and CD14 expression by BMDM (Fig 9B). In contrast to CD38 and CD14, ABCA1 levels were significantly reduced following IFNγ treatment, as previously described [38]. To determine whether IFNγ is required for the TP cell generation in vivo, we infected IFNγ KO mice. CD38 expression was lower, and fewer TP cells were detected compared to WT mice (Fig 9C). Thus, both in vitro and in vivo observations demonstrate that IFNγ drives the generation of TP cells that are highly infected.

CD11cHi MDC are highly infected by Mtb late during infection

We next addressed how TP cells evolve over time. Among non-PMN myeloid cells, there were few CD38+CD14+ cells two weeks after infection (Fig 10A). By 3 wpi, a discrete population of CD38+CD14+ cells was detected, and by 6 wpi, ~20% of non-PMN myeloid cells expressed CD38 and CD14 (Fig 10A). The kinetics of the development of CD38+CD14+ cells parallels the recruitment of T cells to the lung and is consistent with a role for IFNγ in the expression of CD38 and CD14 (Fig 9B and 9C). TP cells were located primarily in the lung parenchyma consistent with their high rate of infection (Fig 10B and 10C). Overtime, MerTK and CD64 expression increased on CD38+CD14+ cells and ultimately, most CD38+CD14+ myeloid cells expressed MerTK+ and CD64, similar to the IM population defined by Huang et al [13]) (Fig 10A). Indeed, as IM increased in abundance in the lung between 3 and 6 wpi (Fig 1H, Fig 10A), the majority expressed CD38 and CD14 (Fig 10D). Importantly, it is this population (i.e., CD38+CD14+Mertk+CD64+) which is highly infected (Fig 10E).

Fig 10. TP CD11cHi MDC are frequently infected by Mtb.

Fig 10

A. CD64 and MerTK expression by CD14+/CD38+ myeloid cells at 2, 3, or 6 weeks after Mtb infection. B. CD14+/CD38+ myeloid cells (i.e., “Q2”) are exclusively located in the lung parenchymal compartment while 35% of the CD14-/CD38- myeloid cells (i.e., “Q4”) are in the vasculature staining from intravenously administered anti-CD45 mAb. C. Quantification of parenchymal location of CD14+/CD38+ myeloid cells CD38 staining (from Fig 10B) (left) and the frequency of YFP+ cells among the four subsets (right). D. A majority of CD64+/MerTK+ myeloid “IM” cells express CD14 and CD38, 3 and 6 wpi. E. The frequency of YFP+ cells among CD64+/MerTK+ myeloid “IM” cells based on their expression of CD14 and CD38 expression at 3 and 6 wpi. F. The frequencies of CD11cHi MDC, AM and CD103 DC among myeloid cells after infection with Rv.YFP over time. Error bars, SD. *, p<0.05; t-test compared to the prior timepoint. Each time point represents five mice. G. The infection rate (%YFP+) for each of the seven myeloid cell types (top row) and the contribution of each cell type to the total YFP+ population (bottom row). Non-PMN myeloid cells (A-E) or total myeloid cells (F, G) were analyzed. Each time experimental group consists of five mice and is representative of at least two independent experiments.

While the relative abundance of AM declined during infection, AM still represented 10% of all myeloid cells through four months after infection (Fig 10F). In contrast, CD11cHi MDC rapidly increased between two and three weeks after infection and became the dominant mononuclear myeloid population by six weeks and continued to increase through four months post-infection. At three-, six-, and 16-weeks post infection, CD11cHi MDC had the highest rate of infection, although as time passed, the overall frequency of Mtb-infected cells declines (Fig 10G, top row; S6 Fig). We next calculated the distribution of Rv.YFP+ cells among the seven different myeloid cell types. After three weeks, most Mtb was detected in AM, monocytes, CD11cHi MDC and PMNs. However, by six weeks, most Mtb was found in CD11cHi MDC (Fig 10G, bottom row). Interestingly, not only did AM and CD11cHiMDC express high levels of class II MHC, but Mtb-infected AM and CD11cHiMDC, expressed similarly high cell surface class II MHC (Fig 11; S6 Fig). In contrast, only RM had heterogenous class II MHC expression. Thus, although there was no evidence that Mtb inhibited class II MHC expression, it remains to be determined whether infected cells expressing low levels of class II MHC could impair CD4 T cell recognition and control of intracellular infection. Considering the prominent infection rate of TP cells compared to non-TP cells, these data show that parenchymal TP CD11cHi MDC cells are important cellular location for Mtb in the mouse lung.

Fig 11. Mtb-infected CD11cHi MDC have high class II MHC expression.

Fig 11

Class II MHC expression by uninfected and Mtb-infected (i.e., YFP+) non-PMN myeloid cells, or the AM, RM, and CD11cHi MDC subsets from the lungs of C57BL/6 mice, three and six weeks after infection by aerosol route with ~100 Rv.YFP. Numbers represent the quadrant means ± SD (n = 4–5 mice/time point).

Discussion

The lack of definitive lineage markers that can identify discrete cell types during inflammation makes it difficult to determine whether certain types of myeloid cells ineffectively control bacterial replication and develop into a cellular niche where Mtb evades adaptive immunity. While Mtb initially infects AM, different cell types become infected as the infection progresses, and it isn’t always clear whether differences in cell surface markers identify unique cell types or distinct activation states [1012, 21, 28]. Improvements in multiparametric flow cytometry, the availability of fixation-stable fluorochromes and recombinant mycobacterial strains expressing fluorescent proteins have improved the capacity to study Mtb-infected cells ex vivo [9, 13, 22, 29]. We used an antibody panel which took advantage of SiglecF, a marker specific for AM and eosinophils, and our dump channel excluded lymphocytes, which express “myeloid markers” when activated, including CD11b and CD11c. We determined that YFP MFI could differentiate infected from uninfected cells and correlated with the MOI of Rv.YFP. Combining these tools allowed us to identify and sort YFPpos vs. YFPneg AM, CD11cHi MDC, and RM from the lungs of infected mice. By comparing uninfected and infected cells within the same infected animal provided data on how these cells respond to infection.

Previously, Rothchild et al showed that the early innate AM response to Mtb (i.e., ≤10 days after infection) is characterized by a NRF2-driven response and is relatively anti-inflammatory [22]). This early phase of infection is notable for its lack of an inflammatory response and a delay T cell priming. In contrast, we find that infected AM are can be characterized by a pro-inflammatory state three weeks post-infection, during which time a robust Th1 response has been recruited to the lung. The infected AM population has a gene expression signature consistent with both an infected state (e.g., TLR signaling) and recognition by T cells (e.g., IFNγ signaling). Using a high dose intranasal Mtb model, Huang et al find that recruited macrophages (i.e., IM) are better at controlling Mtb growth than AM [13]. Our results after low-dose aerosol Mtb infection overlap considerably with their results. However, comparison of infected AM to uninfected AM from mice three to six weeks after infection, shows that Mtb-infected AM are highly activated, upregulated IFNγ-regulated genes (e.g., NOS2, H-2, CD274 and CD38), upregulated IL-1 and COX-2, and downregulate Alox5 and PPARγ, compared to uninfected AM, all of which should foster an environment that restricts bacillary growth [34, 3941]. An important caveat is our inability to discern whether the intracellular Mtb were alive or dead, as it is possible that T cells interact with macrophages containing dead bacteria. Nevertheless, the pulmonary T cell response peaks 3–4 weeks after infection, which is coincident with the deacceleration of bacterial growth, and the onset of immune control. Thus, T cell mediated control of infection correlates with the T cell activation of Mtb-infected cells.

We identified 25 genes that were significantly upregulated in Mtb-infected versus uninfected cells, in all three macrophage populations (i.e., AM, CD11cHi MDC, and RM). Among these, we validated the expression of CD14, CD38, ABCA1, and podoplanin by flow cytometry. Co-expression of CD14, CD38, and ABCA1 identified a population of highly infected lung myeloid cells. While CD14 is the receptor for LPS, it is also mediates uptake of Mtb and apoptotic cells [42, 43]. CD38 is an ectoenzyme that generates cyclic ADP-ribose and regulates intracellular calcium [44, 45]. ABCA1 is a cholesterol efflux pump regulated by PPARγ, a transcription factor that profoundly affects Mtb survival [39, 46, 47]. Finally, podoplanin is associated with the phagocytic potential of macrophages [48]. Thus, these molecules are positioned to restrict bacillary growth, or be subverted by Mtb to promote its survival.

We entertained four hypotheses to explain the high rate of Mtb-infection in these “triple-positive” cells. One was that CD14, CD38, and ABCA1 expression identify macrophages that are prone to infection. However, our ex vivo phagocytosis assay showed that TP cells from the lungs of infected mice were not preferentially infected. A second hypothesis was that these molecules were induced by intracellular Mtb. However, a large fraction of TP cells remained uninfected, excluding this possibility. Third, we considered whether the high infection rate of TP cells was secondary to the propensity to migrate into the parenchyma [9]. However, CD14 and CD38 single positive cells were also in the parenchyma; thus, location cannot account for the high infection rate of CD14+CD38+ cells. Our fourth hypothesis was that T cell recognition of infected cells drives macrophage activation and the expression of these surface markers. Indeed, the kinetics of T cell recruitment to the lung correlates with the appearance of TP cells, and IFNγ potentiates CD38 and CD14 induction. While ABCA1 expression can be inhibited by IFNγ [49], its regulation in vivo is likely to be more complicated as its level is affected by the local accumulations of cholesterol or other lipids. This hypothesis is supported by the IFNγ and TNF-driven gene signature of infected cells and is consistent with IFNγ’s role in promoting CD38 expression, a recognized M1 marker [50].

Classifying different macrophages during inflammatory states is challenging because they are recruited, differentiate and become activated. We developed an antibody panel and gating schemes to distinguish distinct populations of myeloid cells based on our current understanding of myeloid cell ontogeny, which provides a clear framework for their classification [5]. This approach divides lung myeloid cells into tissue resident cells: AM (embryonic origin), CD103DC and CD11bDC (i.e., cDC1 and cDC2, from DC precursors) [51]. Other myeloid cells recruited to the lung, particularly during inflammation, are largely derived from monocytes. At steady-state, 2–3 distinct populations of interstitial macrophages (IM) have been described in an infected lung tissue [1, 2, 52]. These IM express CD64 and MerTK and are distinguished from AM by their higher expression of CD11b and MHCII, lower expression of CD11c, and absence of SiglecF. Monocyte-derived macrophages appear in the lung during inflammation such as tuberculosis [27, 53]. Mtb initially infects AM, which translocate into the lung interstitium [9, 22]. Following bacterial replication and AM cell death, the dispersed bacteria infect other cells. Three weeks after infection, most lung macrophages (i.e., MerTK+CD64+) are AM accompanied by few IM (Fig 1H). We find that most intracellular Mtb was in cells that previously referred to as CD11bDC [27], but based on new data we now believe these cells are recruited monocytes (e.g., Ly6cHiCX3CR1HiMerTK-ve) that differentiate into macrophages. Although we cannot rule out that some “true” CD11bDC are among the Mtb-infected cells, their overall gene expression pattern was similar to monocyte-derived macrophages (MDM, MoMa) [54], which others call IM [13], monocyte-derived DC (MoDC) [55], or MDC [32]. Eventually, the major cell population infected by Mtb is CD11b+CD11chiMHCIIhiMerTK+Ly6Clo MDC that express CD14, CD38, and ABCA1. In addition, we detect a population of CD11b+CD11cloMerTK-Ly6Clo myeloid cells that we call RM. In uninfected mice, most cells with an RM phenotype, are in the vasculature, and could be Ly6Clo monocytes [27]. However, nearly all of the YFP+ RM in the parenchyma are distinct from CD11cHi MDC, based on their cytometric phenotype and transcriptional profile. These cells represent a minor fraction of the total Mtb infected cells in the lung.

The degree to which our murine model informs us about human disease is an important consideration. Macrophages with a cell surface phenotype of CD11cHiCCR2+CX3CR1+ are found in the intestinal wall of subjects with inflammatory bowel disease and are thought to be derived from CD14+ monocytes [56, 57]. A limited number of studies have described the diversity of human myeloid cells during lung inflammation [58, 59], defined by their expression of CD206, CD11b, CD11c, CD14, and CD64. In macaque and human granulomas, proinflammatory macrophage expressing CD163, CD68, HAM56, and iNOS are observed predominantly in the inner region of the lesions granulomas [60]. It remains to be determined if these macrophages are the human equivalent of murine CD11cHiMDC.

The basis for restrictive versus permissive granulomas may be linked to how T cells recognize and inhibit intracellular bacterial growth, which could vary by the local lung microenvironment, the cell type infected, and the ability of the bacilli to evade detection [61, 62]. Increasingly, AM are regarded as a protected niche occupied by Mtb, as host resistance is enhanced following AM depletion in the mouse model [13, 14]. However, AM were depleted at an early stage of infection (2 wpi) in those studies, before the full impact of T cell immunity is manifest in the lung. Whether the difference between the ability of AM and IM to restrict bacterial growth is an intrinsic difference, and whether it can be modified through interactions with T cells will require additional studies. It is striking that in our study, two opposing forces are at work. On the one hand, immunity leads to a diminishing rate of infection, particularly among CD11cHi MDC, which falls from ~20% at 3 wpi, to 3% by 16 wpi. On the other hand, CD11cHi MDC, which express CD14, CD38, and ABCA1, become highly infected overtime, and nearly 75% of Mtb is found in these cells. Why do these cells develop into a major reservoir of Mtb is not clear; nor whether they are permissive or restrictive. Despite the high expression of MHCII molecules by CD11cHi MDC, these cells might be poor APC [63]. We and others find that T cells are not efficient at recognizing macrophages containing few bacteria, and this could be an important mechanism of immune evasion in vivo [64, 65]. We expect that by defining the CD38+CD14+ABCA1+ CD11cHi MDC as a cell type that is abundantly infected both early and late after Mtb infection, we gain insight into how Mtb persists in vivo despite a vigorous anti-bacterial immune response and make possible strategies designed to target Mtb-infected macrophages.

Methods

Ethics statement

Studies involving animals were conducted following relevant guidelines and regulations, and the studies were approved by the Institutional Animal Care and Use Committee at the University of Massachusetts Medical School (Animal Welfare A3306-01), using the recommendations from the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the Office of Laboratory Animal Welfare.

Mice

C57BL/6J, Rag-1-deficient (B6.129S7-Rag1tm1Mom), IFN-gamma KO (B6.129S7-Ifng<tm1Ts>/J), MyD88 KO [B6.129P2(SJL)MyD88] mice were purchased from Jackson Laboratories (Bar Harbor, ME). All animal protocols used herein were approved by University of Massachusetts Medical School Animal Care and Use Committee.

Generation of BMDCs and BMDM

Bone marrow cells were harvested from wild type C57BL/6 or MyD88 KO mice and were differentiated into BMDC and BMDM according to the protocols previously reported [21, 66]. BMDCs were prepared by culturing bone marrow cells in RPMI1640 medium (Gibco, Gaithersburg, MD) 10% fetal bovine serum (FBS) (Sigma), and 50 μM 2-mercaptoethanol, 10 mM HEPES, 2 mM L-Glutamine (complete media), supplemented with 10 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF, R&D Systems, MN) for 8 days. Fresh media was added on days 2 and 4 to maximize BMDC yield. Non-adherent DCs were collected from 100 mm petri dishes by pipetting, counted, and plated in desired culture plates. BMDM were also generated from wild type C57BL/6 or MyD88 KO mice. BMDMs were prepared by culturing in complete media supplemented with 20% L929 conditioned medium for 8 days. Adherent cells were detached by using trypsin/EDTA solution (Gibco) for 10 min at 37°C.

Construction of YFP-expressing Mtb H37Rv

Bacteria expressing yellow fluorescent protein (sfYFP) were generated by transformation of H37Rv with plasmid PMV261, which constitutively expresses sfYFP under the control of the hsp60 promoter.

In vitro infection

Rv.YFP was grown in BD Difco Middlebrook 7H9 (Thermo Fisher, Waltham, MA) supplemented with 10% OADC (Sigma-Aldrich, St. Louis, MO), 0.2% glycerol and 0.05% Tween-80 (both from Thermo Fisher) to an OD600 of 0.8–1.2, opsonized with TB coat (RPMI 1640, 1% heat-inactivated FBS, 2% human serum, 0.05% Tween-80), washed again and filtered through a 5-micron filter to remove bacterial clumps. The bacteria were counted using a Petroff-Hausser chamber and added to the culture at certain multiplicities of infection.

In vivo infection and lung cell preparation

YFP-Rv was grown to an OD600 of 1.2 and was aliquoted to cryogenic vials, which were stored in a -80°C freezer until use. A bacterial aliquot was thawed, sonicated in a cup-horn sonicator (Branson Ultrasonics Corporation, Danbury, CT) for 1 minute and then diluted in PBS-0.01% Tween-80 to 5 ml. The bacterial inoculum was previously titrated to deliver around 100 CFU to each animal. The inoculum was added to the nebulizer of a Glas-Col Inhalation Exposure System (Glas-Col LLC, Terre Haute, IN), and mice were exposed to infectious aerosol for 30 min. The number of Mtb deposited in the lungs was determined for each experiment, by plating undiluted lung homogenate from a subset of the infected mice within 24 hours of infection. The inoculum varied ranging between 37–90 CFU. To isolate total lung leukocytes, lungs were perfused by slowly injecting PBS into right ventricle immediately after mice were killed. The lungs were minced with a gentleMACS dissociator (Miltenyi) and digested (30 min, 37°C) in 250 U/ml collagenase and 60 U/ml DNase (both from Sigma-Aldrich). Lung cell suspensions were passed through a 70-μm and 40-μm strainers sequentially to remove cell clumps. Lung cells were resuspended in autoMACS running buffer (Miltenyi) that contains BSA, EDTA, and 0.09% sodium azide for subsequent staining.

Flow cytometry analysis

The Ab panel to define 7 myeloid subsets consisted of anti-CD45 (clone 30-F11) labeled with BV650, anti-Ly6G (clone 1A8) with APCfire 750, anti-CD11c (clone N418) with APC, anti-Siglec F (clone E50-2440) with PE, anti-CD11b (clone M1/70) with BV421, anti-Ly-6C (clone HK1.4) with PerCP-Cy5.5, anti-CD103 (clone M290) with BUV395,. The dump channel was used to exclude T cells, B cells, and NK cells for efficient myeloid cell analysis and included anti-Thy1.2 (clone 30H12), anti-CD19 (clone 6D5), and anti-NK1.1 (clone PK136) with PE-Cy7. The Ab panel to define myeloid subsets and TP cells included anti-CD45 (clone 30-F11) labeled with BV650, anti-CD38 (clone 90) with AF-647, anti-CD11b (clone M1/70) with AF594, anti-Abca1 (clone 5A1-1422) with PE, anti-Ly-6C (clone HK1.4) with PerCP-Cy5.5, anti-Siglec F (clone E50-2440) with APC-R700, anti-CD14 (clone Sa14-2) with APC-Cy7, anti-CD103 (clone M290) with BUV395, anti-CD11c (clone N418) with BV421. The dump channel for this Ab panel included anti-Thy1.2 (clone 30H12), anti-CD19 (clone 6D5), anti-NK1.1 (clone PK136), and anti-Ly6G (clone 1A8) with PE-Cy7. The Ab panel for Aurora to define iNOS and IL-1 beta in addition to myeloid subsets and TP cells includes anti-CD45 (clone 30-F11) labeled with BV650, anti-Ly6G (clone 1A8) with APCfire 750, anti-CD38 (clone 90) with Pacific Blue, anti-CD11b (clone M1/70) with BV421, anti-Abca1 (clone 5A1-1422) with PE, anti-CD11c (clone N418) with BV570, anti-Siglec F (clone E50-2440) with APC-R700, anti-CD14 (clone Sa2-8) with PerCP-eFluor710, anti-CD103 (clone 2E7) with BV711, anti-Ly-6C (clone HK1.4) with PerCP-Cy5.5, anti-CD11c (clone N418) with BV421, anti-iNOS (clone CXNFT) with PE-eFluor610, and anti-IL-1 beta (clone NJTEN3) with APC. NJTEN3 recognizes pro-form of IL-1b. The dump channel for this Ab panel included anti-Thy1.2 (clone 30H12), anti-CD19 (clone 6D5), and anti-NK1.1 (clone PK136). Abs were purchased from either Biolegend, BD, or eBiosciences. Live/dead viability staining was done using Zombi Aqua (Biolegend).

Freshly prepared lung cells were incubated with 5 ug/ml of anti-mouse CD16/32 (clone 2.4G2, BioXCell, Lebanon, NH) for 10 min at room temperature to block non-specific binding through Fc receptors. Then, the same volume of Ab cocktail was added, and cells were incubated with Abs for 30 min at 4°C. Staining for Fc block and surface markers was done in autoMACS running buffer. Cells were then washed with PBS and stained with Zombi Aqua diluted in PBS. For intracellular staining of iNOS and IL-1 beta, lung cells were stained ex vivo without in vitro stimulation. The lung cells were first stained for cell surface markers and live/dead viability, and then fixed and permeabilized using Perm/Fix reagents (BD) according to the manufacturer’s recommendation. For ICS staining, cells were incubated in perm buffer (BD) containing an antibody cocktail diluted for 20 min at 4°C.To inactivate the bacteria, samples were fixed with 1% paraformaldehyde/PBS for 1 hour at room temperature and then washed with MACS buffer. FlowJo Software (Tree Star, Portland, OR) was used to analyze the data. Single cells were gated by forward scatter area versus height and dead cells were excluded by live/dead staining.

Cell sorting

Cells were sorted using BD FACSAria IIU Cell Sorter located in the biosafety level 3 lab in University of Massachusetts Medical School. WT C57BL/6 mice were infected with YFP-Rv intratracheally at an inoculum of 5000. This high dose of YFP-Rv was intended to obtain sufficient numbers of infected cells sorted for Genechip analysis. 3 weeks later, Lung cell suspensions were obtained and stained for surface markers, so that YFP- and YFP+ cells from each AM, CD11cHi MDC, and RM were sorted. Because the maximum number of cell separation is four with the sorter, only two subsets of myeloid cells were collected at each experiment. The Ab panel for sorting AM and CD11b DC includes anti-CD45 (clone 30-F11) labeled with BV650, anti-CD11c (clone N418) with PerCP-Cy5.5, anti-CD11b (clone M1/70) with BV421, anti-CD103 (clone 2E7) with PE-Cy7, anti-Siglec F (clone E50-2440) with APC-R700. The Ab panel for sorting CD11cHi MDC and RM includes anti-CD45 (clone 30-F11) labeled with BV650, anti-CD11c (clone N418) with APC, anti-CD11b (clone M1/70) with BV421, anti-CD103 (clone 2E7) with PerCP-Cy5.5, anti-Siglec F (clone E50-2440) with PE-Cy7, anti-Ly6C (clone HK1.4) with AF700, Ly6G (clone 1A8) with APC-Cy7. Cells were stained with Zombi Aqua to exclude dead cells. Target cells were separated 4-way through 85 um nozzles into polypropylene FACS tubes containing 2 ml of FBS.

GeneChip analysis

Cells were obtained from 3–5 individual mice for each cell type, from two independent experiments. Sorted cells were subjected to RNA isolation by using Trizol according to the manufacturer’s protocol. The isolated RNA was used to generate cRNA which was then biotinylated and prepared according to the Affymetrix GeneChip 3′ IVT Express Protocol from 150 ng of total RNA. Following fragmentation, 10 μg of cRNA was hybridized for 16 h at 45°C on Mouse Clariom D arrays (Thermo Fisher). Arrays were washed and stained in the Affymetrix Fluidics Stations 450. The arrays were scanned using an Affymetrix GeneChip Scanner 3000 7G. Initial QC was performed with Transcription Analysis Console 3 using the RMA algorithm with quantile normalization and general background correction. Samples that failed QC were excluded from further analysis. Genes differentially expressed between YFP- and YFP+ cells within each subset were determined at a false discovery rate (FDR) of 0.05, a fold change ≥2, and an absolute expression of >120. Heat maps were made using Morpheus (https://software.broadinstitute.org/morpheus) using hierarchical clustering by rows and row normalization. Venn diagrams were made using BioVenn [67]. Gene enrichment scores were determined using the Gene Set Enrichment Analysis (GSEA) program [68, 69], along with the MSigDB v6.2 gene signature database. Inguenity was used to predict the upstream regulators and predict the most affected canonical cellular pathways. As described above, genes differentially expressed between YFP+ and YFPneg cell populations (FC≥2; absolute expression >120) were used as input data and the results are reported as log10(p value) and in the case of the canonical pathway prediction, whether the pathway is predicted to be activated or inhibited.

Supporting information

S1 Fig. Identification of 7 populations of myeloid cells in the lungs of Mtb-infected mice.

CD11b and CD11c are frequently used to distinguish alveolar macrophages (AM) from pulmonary dendritic cells (DC): AM are generally CD11bloCD11chiMHCIIlow-int, while DC are CD11bint-hiCD11chiMHCIIhi. This strategy works well for uninfected mice housed under conventional conditions. However, during inflammation, AM upregulate both CD11c and MHCII. Therefore, the following scheme takes advantage of SiglecF to identify AM, independently of MHCII. Single cell suspensions obtained from the lungs of mice were gated based on (a) scatter, (b) singlets, and then dead cells excluded (c). Leukocytes in the lung were identified based on CD45 staining (d) and lymphoid cells were excluded by using a dump channel that consisted of anti-Thy1, CD19, and NK1.1 (e). Neutrophils (PMNs, “1”) were identified based on Ly6g expression (f). AM (“2”) were identified by their siglecFHiCD11cHi phenotype, while eosinophils (Eos, “3”) expressed lower amounts of SiglecF and no CD11c (i.e., siglecFintCD11c-) (g). CD11cintCD11bHi cells were identified as recruited macrophages (RM, “5”) and monocytes, and monocytes were further distinguished by their Ly6C expression (“4”). Finally, the remaining CD11cHi cells were designated as DC, and 2 different subsets identified by their expression of CD103 (i.e., CD103DC or cDC1, “6”) or CD11b (i.e., CD11bDC or cDC2, “7”). In the Mtb infected lung, siglecF-CD11cHiCD11bHi cells are likely to be a mixture of CD11bDC and CD11cHi MDC.

(PDF)

S2 Fig. A “Dump” strategy excludes lymphoid cells.

In addition to eliminating debris, doublets, and dead cells from our analysis, an essential part of our strategy was to exclude lymphoid cells. After gating on CD45+ cells, lymphoid cells were identified by using a “dump” gate consisting of a mixture of antibodies specific for Thy1, CD19, and NK1.1 (a). Although these markers primarily identify lymphoid cells, some lymphoid cells are known to express low levels of CD11b, CD11c, and SiglecF, particularly when activated, which could lead to misclassification of cell types. Although there are few Dump+ cells that express CD11b, CD11c, or SiglecF in the lungs of uninfected mice (b, c), one sees a more complicated pattern of CD11b and CD11c expression by CD45+ cells by cells isolated from the lungs of Mtb-infected mice (S2b, left), by CD45+dump- cells (center), or by lymphoid cells (right). This strategy is even important when CD11b, CD11c, and SiglecF staining are used to identify lung myeloid cells (c). Thus, our staining panel and gating strategy identify seven major populations of distinct myeloid cells that are present in the lungs, independently of M. tuberculosis infection. This strategy facilitates accurate enumeration of myeloid cells and measurement of phenotypic changes during infection, independent of the markers used to identify the different cell populations. A possible confounder is whether activated myeloid cells express Thy1, CD19, or NK1.1 lineage markers. Analysis of Mtb-infected RAG knockout mice, which lack B and T cells but still have NK cells, shows that few if any activated cells (i.e., MHCII+) in the AM or MDC gate express the “dump markers” (d). As for the RM population, there were “Dump+” cells, which were presumably NK cells, but none in the MHCII+ region. The cells show up in the RM gate as they lack expression of the other markers used to identify distinct myeloid populations (i.e., they lack SiglecF, CD11c, Ly6c, and MHCII). Additionally, we determined the percentage of cells in the dump channel that were YFP+ (e). Cells in the myeloid gate were ~30 times more likely to be infected than cells in the dump gate (~4.2% vs 0.14%). Thus, the dump channel excludes very few infected cells from subsequent analysis.

(PDF)

S3 Fig. Identification of AM, CD103DC, and CD11bDC during Mtb infection.

CD11b and CD11c can be used to discriminate AM and DC in uninfected mice; however, they need to be used in conjunction with other markers during Mtb infection. For example, in uninfected mice, CD11bloCD11chi cells are mostly AM (S3A Fig, left panel). Further analysis of the R1 gate shows that most of the cells are AM with some CD103DC (S3B Fig, top left panel). Similarly, CD11bhiCD11chi cells (S3A Fig, R2 gate) are nearly all CD11bDC (S3B Fig, bottom left panel). However, during Mtb infection, the pattern is more complex. The few CD11bloCD11chi cells (S3A Fig, R1 right panel) are a mixture of AM and DC (S3B Fig, R1), and the CD11bhiCD11chi cells are mostly CD11bDC and MDC but also AM (S3B Fig, R2). In contrast, using the gating scheme described above (S1 Fig), AM and eosinophils are unambiguously identified based on siglecF and CD11c, independently of infection (S3C Fig). The CD11chisiglecFlo cells define DC (Fig 3C, “DC gate”), while the CD11clow-intermsiglecFlo cells are RM and monocytes. The cells in the DC gate include both CD103DC and DC11bDC before infection, but after infection, CD11bDC dominate. As we discuss later, we think that although there are CD11bDC in this population, most of the cells are CD11chi monocyte-derived cells (CD11chi MDC).

(PDF)

S4 Fig. Gene expression analysis of YFP+ “CD11bDC” from the lungs of Mtb-infected mice reveals that they closely resemble CD11cHi MDC.

A. Using well-described transcriptional gene signatures for AM, macrophages, DC and monocytes [2, 32], YFPpos AM, CD11cHi MDC, and RM were compared to well-defined lung myeloid cell populations from uninfected mice (data from www.Immgen.org) using a heat map with global normalization. The YFPpos AM have a transcriptional profile matching AM, while YFPpos CD11cHi MDC and resemble the monocyte/macrophage lineage. B. We developed a 21 gene signature (here, referred to as “ImmGen 1”) that distinguishes ImmGen DC from macrophages. An analysis using the expression of the 15 genes that are preferentially expressed in macrophages (top), the 6 genes that are preferentially expressed in DC (middle), or the combined 21 gene signature is quantified for 43 myeloid unique ImmGen myeloid cell populations, grouped by cell type. Red bar, median. pDC, plasmacytoid DC. Blue, ImmGen lung populations. C. The list of genes that make up the 21 gene signature.

(PDF)

S5 Fig. Infected cells display disproportionately high expression of Podoplanin.

Lung cells were obtained from uninfected mice, or mice four weeks after aerosol infection with Rv.YFP. Podoplanin expression was analyzed by flow cytometry after gating on live CD45+ cells, excluding T cells, B cells, NK cells, and PMN. The black numbers are the percentage of events in each quadrant. The red numbers are the percentage of YFP-ve or YFP+ve events that express podoplanin.

(PDF)

S6 Fig. Distribution of Mtb among different cell types and expression of MHC II by infected cells late during infection.

The H37Rv.YFP strain we use was transformed using a plasmid that expresses sfYFP driven by a constitutive promoter. These plasmids are lost over time and at late timepoints (≥16 wpi) most infected cells no longer express the plasmid based on the lack of fluorescence of CFU grown from lung homogenates. Thus, we cannot rule out that there was preferential plasmid loss in certain cell types or differential degradation of YFP. However, myeloid cells could still be detected at late time points up till 9 months after infection. The distribution of YFP among different cell types (A) and their expression of MHC II (B) 4 months after infection follows a similar trend as observed at 3 and 6 wpi (see Figs 9 and 10). However, because of the issue of plasmid loss, one must interpret these data cautiously.

(PDF)

Data Availability

All gene expression files are available from the GEO database (accession number: GSE146127). All other relevant data are within the manuscript and its supporting information files.

Funding Statement

This study was funded by grants to SMB from the National Institutes of Health (R01 AI106725, R01 AI123286). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Schyns J, Bai Q, Ruscitti C, Radermecker C, De Schepper S, Chakarov S, et al. Non-classical tissue monocytes and two functionally distinct populations of interstitial macrophages populate the mouse lung. Nat Commun. 2019;10(1):3964 Epub 2019/09/05. 10.1038/s41467-019-11843-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Gibbings SL, Thomas SM, Atif SM, McCubbrey AL, Desch AN, Danhorn T, et al. Three Unique Interstitial Macrophages in the Murine Lung at Steady State. Am J Respir Cell Mol Biol. 2017;57(1):66–76. 10.1165/rcmb.2016-0361OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38(1):79–91. Epub 2013/01/01. 10.1016/j.immuni.2012.12.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Scott CL, Henri S, Guilliams M. Mononuclear phagocytes of the intestine, the skin, and the lung. Immunol Rev. 2014;262(1):9–24. Epub 2014/10/17. 10.1111/imr.12220 . [DOI] [PubMed] [Google Scholar]
  • 5.Guilliams M, Mildner A, Yona S. Developmental and Functional Heterogeneity of Monocytes. Immunity. 2018;49(4):595–613. Epub 2018/10/18. 10.1016/j.immuni.2018.10.005 . [DOI] [PubMed] [Google Scholar]
  • 6.Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol. 2014;14(8):571–8. Epub 2014/07/19. 10.1038/nri3712 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gleeson LE, O'Leary SM, Ryan D, McLaughlin AM, Sheedy FJ, Keane J. Cigarette Smoking Impairs the Bioenergetic Immune Response to Mycobacterium tuberculosis Infection. Am J Respir Cell Mol Biol. 2018;59(5):572–9. Epub 2018/06/27. 10.1165/rcmb.2018-0162OC . [DOI] [PubMed] [Google Scholar]
  • 8.Berg RD, Levitte S, O’Sullivan MP, O’Leary SM, Cambier CJ, Cameron J, et al. Lysosomal Disorders Drive Susceptibility to Tuberculosis by Compromising Macrophage Migration. Cell. 2016;165(1):139–52. 10.1016/j.cell.2016.02.034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Cohen SB, Gern BH, Delahaye JL, Adams KN, Plumlee CR, Winkler JK, et al. Alveolar Macrophages Provide an Early Mycobacterium tuberculosis Niche and Initiate Dissemination. Cell Host Microbe. 2018;24(3):439–46 e4. Epub 2018/08/28. 10.1016/j.chom.2018.08.001 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Wolf AJ, Linas B, Trevejo-Nunez GJ, Kincaid E, Tamura T, Takatsu K, et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol. 2007;179(4):2509–19. 10.4049/jimmunol.179.4.2509 . [DOI] [PubMed] [Google Scholar]
  • 11.Repasy T, Lee J, Marino S, Martinez N, Kirschner DE, Hendricks G, et al. Intracellular bacillary burden reflects a burst size for Mycobacterium tuberculosis in vivo. PLoS Pathog. 2013;9(2):e1003190 10.1371/journal.ppat.1003190 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Srivastava S, Ernst JD, Desvignes L. Beyond macrophages: the diversity of mononuclear cells in tuberculosis. Immunol Rev. 2014;262(1):179–92. papers2://publication/ 10.1111/imr.12217 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Huang L, Nazarova EV, Tan S, Liu Y, Russell DG. Growth of Mycobacterium tuberculosis in vivo segregates with host macrophage metabolism and ontogeny. J Exp Med. 2018. Epub 2018/03/04. 10.1084/jem.20172020 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Leemans JC, Juffermans NP, Florquin S, van Rooijen N, Vervoordeldonk MJ, Verbon A, et al. Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol. 2001;166(7):4604–11. 10.4049/jimmunol.166.7.4604 . [DOI] [PubMed] [Google Scholar]
  • 15.Behar SM, Divangahi M, Remold HG. Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat Rev Microbiol. 2010;8(9):668–74. 10.1038/nrmicro2387 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Mahamed D, Boulle M, Ganga Y, Mc Arthur C, Skroch S, Oom L, et al. Intracellular growth of Mycobacterium tuberculosis after macrophage cell death leads to serial killing of host cells. Elife. 2017;6 Epub 2017/01/29. 10.7554/eLife.22028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Srivastava S, Ernst JD. Cutting edge: Direct recognition of infected cells by CD4 T cells is required for control of intracellular Mycobacterium tuberculosis in vivo. J Immunol. 2013;191(3):1016–20. 10.4049/jimmunol.1301236 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. Dissemination of Mycobacterium tuberculosis Is Influenced by Host Factors and Precedes the Initiation of T-Cell Immunity. Infection and Immunity. 2002;70(8):4501–9. 10.1128/iai.70.8.4501-4509.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Chackerian AA, Perera TV, Behar SM. Gamma interferon-producing CD4+ T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis. Infect Immun. 2001;69(4):2666–74. 10.1128/IAI.69.4.2666-2674.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Ronacher K, Joosten SA, van Crevel R, Dockrell HM, Walzl G, Ottenhoff THM. Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. Immunol Rev. 2015;264(1):121–37. 10.1111/imr.12257 . [DOI] [PubMed] [Google Scholar]
  • 21.Skold M, Behar SM. Tuberculosis triggers a tissue-dependent program of differentiation and acquisition of effector functions by circulating monocytes. J Immunol. 2008;181(9):6349–60. 10.4049/jimmunol.181.9.6349 . [DOI] [PubMed] [Google Scholar]
  • 22.Rothchild AC, Olson GS, Nemeth J, Amon LM, Mai D, Gold ES, et al. Alveolar macrophages generate a noncanonical NRF2-driven transcriptional response to Mycobacterium tuberculosis in vivo. Sci Immunol. 2019;4(37). Epub 2019/07/28. 10.1126/sciimmunol.aaw6693 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20(2):163–72. Epub 2019/01/16. 10.1038/s41590-018-0276-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Chakarov S, Lim HY, Tan L, Lim SY, See P, Lum J, et al. Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches. Science. 2019;363(6432). Epub 2019/03/16. 10.1126/science.aau0964 . [DOI] [PubMed] [Google Scholar]
  • 25.Atif SM, Gibbings SL, Jakubzick CV. Isolation and Identification of Interstitial Macrophages from the Lungs Using Different Digestion Enzymes and Staining Strategies. Methods Mol Biol. 2018;1784:69–76. Epub 2018/05/16. 10.1007/978-1-4939-7837-3_6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Schyns J, Bureau F, Marichal T. Lung Interstitial Macrophages: Past, Present, and Future. J Immunol Res. 2018;2018:5160794 Epub 2018/06/02. 10.1155/2018/5160794 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Norris BA, Ernst JD. Mononuclear cell dynamics in M. tuberculosis infection provide opportunities for therapeutic intervention. PLoS Pathog. 2018;14(10):e1007154 Epub 2018/10/27. 10.1371/journal.ppat.1007154 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Gonzalez-Juarrero M, Shim TS, Kipnis A, Junqueira-Kipnis AP, Orme IM. Dynamics of macrophage cell populations during murine pulmonary tuberculosis. J Immunol. 2003;171(6):3128–35. Epub 2003/09/10. 10.4049/jimmunol.171.6.3128 . [DOI] [PubMed] [Google Scholar]
  • 29.Mayer-Barber KD, Andrade BB, Barber DL, Hieny S, Feng CG, Caspar P, et al. Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity. 2011;35(6):1023–34. 10.1016/j.immuni.2011.12.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Mishra BB, Lovewell RR, Olive AJ, Zhang G, Wang W, Eugenin E, et al. Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis. Nat Microbiol. 2017;2:17072 Epub 2017/05/16. 10.1038/nmicrobiol.2017.72 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol. 2012;13(11):1118–28. 10.1038/ni.2419 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Menezes S, Melandri D, Anselmi G, Perchet T, Loschko J, Dubrot J, et al. The Heterogeneity of Ly6C(hi) Monocytes Controls Their Differentiation into iNOS(+) Macrophages or Monocyte-Derived Dendritic Cells. Immunity. 2016;45(6):1205–18. Epub 2016/12/22. 10.1016/j.immuni.2016.12.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Mishra BB, Rathinam VA, Martens GW, Martinot AJ, Kornfeld H, Fitzgerald KA, et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat Immunol. 2013;14(1):52–60. 10.1038/ni.2474 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A. 1997;94(10):5243–8. 10.1073/pnas.94.10.5243 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Richardson MB, Williams SJ. MCL and Mincle: C-Type Lectin Receptors That Sense Damaged Self and Pathogen-Associated Molecular Patterns. Front Immunol. 2014;5:288 Epub 2014/07/09. 10.3389/fimmu.2014.00288 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Miyake Y, Toyonaga K, Mori D, Kakuta S, Hoshino Y, Oyamada A, et al. C-type lectin MCL is an FcRgamma-coupled receptor that mediates the adjuvanticity of mycobacterial cord factor. Immunity. 2013;38(5):1050–62. Epub 2013/04/23. 10.1016/j.immuni.2013.03.010 . [DOI] [PubMed] [Google Scholar]
  • 37.Mogues T, Goodrich ME, Ryan L, LaCourse R, North RJ. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. The Journal of experimental medicine. 2001;193(3):271–80. 10.1084/jem.193.3.271://publication/uuid/5C30A1AA-7943-43E3-A68F-AFC3F62EE4CA. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hao XR, Cao DL, Hu YW, Li XX, Liu XH, Xiao J, et al. IFN-gamma down-regulates ABCA1 expression by inhibiting LXRalpha in a JAK/STAT signaling pathway-dependent manner. Atherosclerosis. 2009;203(2):417–28. 10.1016/j.atherosclerosis.2008.07.029 . [DOI] [PubMed] [Google Scholar]
  • 39.Arnett E, Weaver AM, Woodyard KC, Montoya MJ, Li M, Hoang KV, et al. PPARgamma is critical for Mycobacterium tuberculosis induction of Mcl-1 and limitation of human macrophage apoptosis. PLoS Pathog. 2018;14(6):e1007100 Epub 2018/06/22. 10.1371/journal.ppat.1007100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Mayer-Barber KD, Sher A. Cytokine and lipid mediator networks in tuberculosis. Immunol Rev. 2015;264(1):264–75. 10.1111/imr.12249 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature. 2014;511(7507):99–103. 10.1038/nature13489 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Khanna KV, Choi CS, Gekker G, Peterson PK, Molitor TW. Differential infection of porcine alveolar macrophage subpopulations by nonopsonized Mycobacterium bovis involves CD14 receptors. J Leukoc Biol. 1996;60(2):214–20. Epub 1996/08/01. 10.1002/jlb.60.2.214 . [DOI] [PubMed] [Google Scholar]
  • 43.Devitt A, Parker KG, Ogden CA, Oldreive C, Clay MF, Melville LA, et al. Persistence of apoptotic cells without autoimmune disease or inflammation in CD14-/- mice. J Cell Biol. 2004;167(6):1161–70. Epub 2004/12/22. 10.1083/jcb.200410057 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Hogan KA, Chini CCS, Chini EN. The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases. Front Immunol. 2019;10:1187 Epub 2019/06/20. 10.3389/fimmu.2019.01187 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Lischke T, Heesch K, Schumacher V, Schneider M, Haag F, Koch-Nolte F, et al. CD38 controls the innate immune response against Listeria monocytogenes. Infect Immun. 2013;81(11):4091–9. 10.1128/IAI.00340-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Rothchild AC, Stowell B, Goyal G, Nunes-Alves C, Yang Q, Papavinasasundaram K, et al. Role of Granulocyte-Macrophage Colony-Stimulating Factor Production by T Cells during Mycobacterium tuberculosis Infection. MBio. 2017;8(5). Epub 2017/10/27. 10.1128/mBio.01514-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Mahajan S, Dkhar HK, Chandra V, Dave S, Nanduri R, Janmeja AK, et al. Mycobacterium tuberculosis modulates macrophage lipid-sensing nuclear receptors PPARgamma and TR4 for survival. J Immunol. 2012;188(11):5593–603. 10.4049/jimmunol.1103038 . [DOI] [PubMed] [Google Scholar]
  • 48.Ugorski M, Dziegiel P, Suchanski J. Podoplanin—a small glycoprotein with many faces. Am J Cancer Res. 2016;6(2):370–86. Epub 2016/05/18. [PMC free article] [PubMed] [Google Scholar]
  • 49.Hao X-r, Cao D-l, Hu Y-w, Li X-x, Liu X-h, Xiao J, et al. IFN-γ down-regulates ABCA1 expression by inhibiting LXRα in a JAK/STAT signaling pathway-dependent manner. Atherosclerosis. 2009;203(2):417–28. 10.1016/j.atherosclerosis.2008.07.029 [DOI] [PubMed] [Google Scholar]
  • 50.Jablonski KA, Amici SA, Webb LM, Ruiz-Rosado Jde D, Popovich PG, Partida-Sanchez S, et al. Novel Markers to Delineate Murine M1 and M2 Macrophages. PLoS One. 2015;10(12):e0145342 Epub 2015/12/25. 10.1371/journal.pone.0145342 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Guilliams M, van de Laar L. A Hitchhiker's Guide to Myeloid Cell Subsets: Practical Implementation of a Novel Mononuclear Phagocyte Classification System. Front Immunol. 2015;6:406 Epub 2015/09/01. 10.3389/fimmu.2015.00406 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Hoffmann F, Ender F, Schmudde I, Lewkowich IP, Kohl J, Konig P, et al. Origin, Localization, and Immunoregulatory Properties of Pulmonary Phagocytes in Allergic Asthma. Front Immunol. 2016;7:107 Epub 2016/04/06. 10.3389/fimmu.2016.00107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T, Takatsu K, et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med. 2008;205(1):105–15. 10.1084/jem.20071367 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Sichien D, Lambrecht BN, Guilliams M, Scott CL. Development of conventional dendritic cells: from common bone marrow progenitors to multiple subsets in peripheral tissues. Mucosal Immunol. 2017;10(4):831–44. Epub 2017/02/16. 10.1038/mi.2017.8 . [DOI] [PubMed] [Google Scholar]
  • 55.Bain CC, Scott CL, Uronen-Hansson H, Gudjonsson S, Jansson O, Grip O, et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol. 2013;6(3):498–510. Epub 2012/09/20. 10.1038/mi.2012.89 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Bernardo D, Marin AC, Fernandez-Tome S, Montalban-Arques A, Carrasco A, Tristan E, et al. Human intestinal pro-inflammatory CD11c(high)CCR2(+)CX3CR1(+) macrophages, but not their tolerogenic CD11c(-)CCR2(-)CX3CR1(-) counterparts, are expanded in inflammatory bowel disease. Mucosal Immunol. 2018;11(4):1114–26. Epub 2018/05/11. 10.1038/s41385-018-0030-7 . [DOI] [PubMed] [Google Scholar]
  • 57.Bujko A, Atlasy N, Landsverk OJB, Richter L, Yaqub S, Horneland R, et al. Transcriptional and functional profiling defines human small intestinal macrophage subsets. J Exp Med. 2018;215(2):441–58. Epub 2017/12/24. 10.1084/jem.20170057 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Baharom F, Rankin G, Blomberg A, Smed-Sörensen A. Human Lung Mononuclear Phagocytes in Health and Disease. Frontiers in Immunology. 2017;8(499). 10.3389/fimmu.2017.00499 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Yu YR, Hotten DF, Malakhau Y, Volker E, Ghio AJ, Noble PW, et al. Flow Cytometric Analysis of Myeloid Cells in Human Blood, Bronchoalveolar Lavage, and Lung Tissues. Am J Respir Cell Mol Biol. 2016;54(1):13–24. Epub 2015/08/13. 10.1165/rcmb.2015-0146OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Mattila JT, Ojo OO, Kepka-Lenhart D, Marino S, Kim JH, Eum SY, et al. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol. 2013;191(2):773–84. 10.4049/jimmunol.1300113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Cadena AM, Hopkins FF, Maiello P, Carey AF, Wong EA, Martin CJ, et al. Concurrent infection with Mycobacterium tuberculosis confers robust protection against secondary infection in macaques. PLoS Pathog. 2018;14(10):e1007305 Epub 2018/10/13. 10.1371/journal.ppat.1007305 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nat Rev Immunol. 2017;17(11):691–702. Epub 2017/07/25. 10.1038/nri.2017.69 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Plantinga M, Guilliams M, Vanheerswynghels M, Deswarte K, Branco-Madeira F, Toussaint W, et al. Conventional and monocyte-derived CD11b(+) dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen. Immunity. 2013;38(2):322–35. Epub 2013/01/29. 10.1016/j.immuni.2012.10.016 . [DOI] [PubMed] [Google Scholar]
  • 64.Patankar YR, Sutiwisesak R, Boyce S, Lai R, Lindestam Arlehamn CS, Sette A, et al. Limited recognition of Mycobacterium tuberculosis-infected macrophages by polyclonal CD4 and CD8 T cells from the lungs of infected mice. Mucosal Immunol. 2019. Epub 2019/10/23. 10.1038/s41385-019-0217-6 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Lewinsohn DA, Heinzel AS, Gardner JM, Zhu L, Alderson MR, Lewinsohn DM. Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells. Am J Respir Crit Care Med. 2003;168(11):1346–52. 10.1164/rccm.200306-837OC . [DOI] [PubMed] [Google Scholar]
  • 66.Lee J, Repasy T, Papavinasasundaram K, Sassetti C, Kornfeld H. Mycobacterium tuberculosis induces an atypical cell death mode to escape from infected macrophages. PLoS One. 2011;6(3):e18367 10.1371/journal.pone.0018367 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Hulsen T, de Vlieg J, Alkema W. BioVenn—a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics. 2008;9:488 Epub 2008/10/18. 10.1186/1471-2164-9-488 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50. Epub 2005/10/04. 10.1073/pnas.0506580102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics. 2007;23(23):3251–3. Epub 2007/07/24. 10.1093/bioinformatics/btm369 . [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Marcel A Behr, Michael R Wessels

20 Mar 2020

Dear Dr. Behar,

Thank you very much for submitting your manuscript "A subset of CD11cHi monocyte-derived macrophages are the dominant niche for Mycobacterium tuberculosis" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Marcel A. Behr

Associate Editor

PLOS Pathogens

Michael Wessels

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: The manuscript by Lee and colleagues titled “a subset of CD11chi monocyte-derived macrophages are the dominant niche for Mycobacterium tuberculosis” addresses a rapidly evolving and highly significant area of tuberculosis research. As our appreciation of macrophage ontogeny and heterogeneity expands it is important to generate a functional appreciation of how the different macrophage subsets contribute to control or progression of tuberculosis in vivo. In this paper the authors describe a new subset of monocyte derived macrophages that are defined by the surface marker profile CD11b+CD11c+ MHCIIhi, and characterized by additional transcriptional profiling. When they examined the distribution of YFP-expressing Mtb in the different macrophage populations they found that these cells contained an unusually high burden of bacteria. On the basis of these observations they refer to these cells as the “dominant niche” for Mtb in the mouse lung (9 times in the text).

I find the data presented in the paper to be of high quality and they are undoubtedly of value to the field at this particular time. However, I think the repeated use of the term “dominant niche”, which implies functional significance beyond mere abundance, to be a considerable exaggeration of what has actually been demonstrated.

1. There is no information on the status of the bacteria in these cells, and they could be fully viable and replicative, or fully under host control.

2. There is no manipulation of this host cell population to demonstrate that they play any role of significance to either disease control or progression. To be able to claim that they are the “dominant niche” one would expect to see some experimental validation.

Absent any functional information the claim that this is the “dominant niche occupied by M tuberculosis long-term” is conjecture. As this remains an unproven hypothesis it should be presented as such and not sold as proven fact. The paper by Huang and colleagues included functional manipulation of cell subsets and demonstrated impact on bacterial burden, and more recently the same group published Dual RNA-seq analysis showing the “matching” stress signatures of pathogen and host cell subset (Pisu et al. Cell Reports 2020). I fully accept that these papers were generated with data from a single early time point and that the conclusions and findings in these papers do not refute the current data in this manuscript, which emphasize later time points in infection progression and probes the granularity of monocyte-derived cell subsets. However, the earlier papers included fitness reporter bacterial strains and experimental manipulation of the cell subsets to demonstrate their functional significance in vivo and the current study lack any comparable data.

The data in the current paper opens the possibility to the presence of a permissive subset of recruited monocyte-derived cells that may have considerable significance post development of an acquired immune response. I agree this is exciting but on the basis of the data presented it is a possibility and not a fact, and its significance remains to be established experimentally.

Reviewer #2: This manuscript by Lee et al examines the intracellular niche of M. tuberculosis (Mtb) during chronic infection. Although this topic has been studied extensively by several other groups, this work does advance new knowledge on the subject. That said, the paper could be written more clearly and in a more focused manner. I have several comments and questions which should be addressed.

Reviewer #3: The ability to distinguish between different cells of the myeloid lineage and their ontogeny particularly macrophages has been a major challenge in the context of Mtb infection. Isolating discrete populations from the heterogenous macrophage populations remains a barrier. In the current submitted manuscript; Lee et al., identify using flow cytometric analysis a subset of CD11chi monocyte derived cells which have an increased presence in the lung post Mtb infection. Moreover these cells seem to be induced or influenced by IFNγ as per their gene expression signature and evidence from the IFNγR KO mouse. In general the manuscript has been prepared thoughtfully and is well written, particularly the discussion. Some minor additions and alterations are needed to fully explain and add clarity to readers on the conclusions of the data presented. The data presented in the study thus far is quite comprehensive and well supported.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: If the authors wish to argue the functional significance of this cell subset as a niche that supports infection they need to include data demonstrating functional impact. However, I would be perfectly satisfied by a more circumspect handling of the interpretation of the data. I think the hypothesis is important, our knowledge of lung macrophages is woefully incomplete, and these data are timely and of value to the field.

Reviewer #2: 1) To me the most important finding of the paper is that the CD11c+CD11b+ myeloid population that is the predominant niche for Mtb during chronic infection, and has been referred to as dendritic cells in most of the TB literature for years are actually monocyte-derived cells that are most akin to macrophages (this is also the title of the manuscript). The best evidence for this would be the RNA-Seq analysis shown in Fig. S4, as the rest of the data does not conclusively make this point. Why is the most important figure shown only as a supplemental figure? The figure legend suggests this is old data that was performed using sorting “based on a limited number of cell surface markers.” If so, as this is the cornerstone of the manuscript, I believe this analysis should be repeated sorting cells using markers that they use throughout the manuscript and that they currently think is optimal. In addition, although the heat maps are helpful, is there a bioinformatic platform that could be utilized to better assess the relatedness between the various populations? I think this central message could be made more clearly and more rigorously. I think this analysis would be an important contribution to the field, but it needs to be done well and to be presented prominently in the paper.

2) , as shown by RNA-Seq (although this data is buried in Fig. S4). Although previous work by the authors and others has shown that at least some of these cells are derived from monocytes, several possibilities have remained: 1) that although some are monocyte derived, most are still conventional DCs that perhaps express some monocyte markers during the inflammatory milieu of TB, or 2) Most are monocyte-derived, but for all intensive purposes they differentiate into cells that are largely indistinguishable from DCs. Although it cannot be ruled out that a small subset of these cells may be true DCs, as the authors acknowledge, Fig S4 is the most convincing data to date that most of these are monocyte-derived cells that most resemble macrophages. This should be highlighted more and I believe this data should be moved to be one of the primary figures.

3) Instead of highlighting the above, the authors seem to spend excessive time (half of Figure 1 and again returning to in in Figure 9), refuting the designation of these cells as interstitial macrophages “IM”, which was a designation made largely in a single paper (Huang et al), and based largely on CD64 and MerTK staining. I believe the point could be made more simply and, again as a subpoint to the fact that these cells are not mostly DCs. The discrepancy in the % of the cells that are MerTK+ (the primary difference between this paper and that of Huang et al.) could perhaps be explained by the dose/route of infection (50-100 CFU by aerosol in this paper vs. 1000 CFU intranasally by Huang), but the biological significance of what % of the macrophages are MerTK+ is not clear and should be de-emphasized.

4) The manuscript uses several different designations throughout the manuscript in reference to these major infected cell type. Initially they are called *CD11bDCs and then switch at various times to calling them different names, including between “CD11c hi MC” and “MDC”. It is understandable that they initially call them CD11bDC as this is what they have been called historically, but the meaning of * is only in the figure legend and thus confusing. However, I believe they should settle then settle on the terminology they want to use and use it consistently thereafter.

5) In the introduction to Figure 2 on p.8, the authors state that “prior studies that identified cell types infected by Mtb using definitions based mostly on CD11b and CD11c, focused on one or two cell types, or looked at early timepoints” and cite several references for this statement. However, ref 9 (Cohen et al) is omitted in this section. Figure 1 in Cohen et al., used a panel of several markers, looked at several myeloid cell types, and arrived at the same nomenclature used here at similar timepoints. Thus, Figure 2 is consistent with and confirms this prior work and this should be acknowledged.

6) The authors use a dump gate of CD19, Thy1, and NK1.1 to exclude B cells, T cells, and NK cells from the myeloid populations they want to look at. These markers are usually lineage specific under non-inflamed conditions, but are the authors sure that these markers are not upregulated on myeloid cells during pulmonary TB? In Fig. S2 they argue that the dump is necessary because B cells/T cells/NK cells upregulate myeloid markers during Mtb infection. However, this same data could also be explained if myeloid cells upregulate CD19, Thy1, or NK1.1.

7) In Fig. 3 the authors show that AM were activated by IFNg and on p. 9 they state, based on this data, that “we infer that T cells are specifically interacting with Mtb-infected AM.” However, I believe it is possible that these AM were activated by bystander IFNg in the absence of a cognate interaction, thus this statement should be softened. To make this statement the authors would need to do MHCII-/- mixed chimeras and show a difference in IFNg activated genes in MHCII+ vs. MCHII- AMs.

8) It is unclear how the predicted pathways were determined in Fig 4D – was this using a bioinformatics approach or purely plotting known stimuli that could be involved in activating macrophages? The graph needs to be explained more clearly. Do the bars represent relative expression or p-value?

9) In Fig 4E-G, the Ingenuity platform used to assess the transcriptional data. I found this graph confusing. I am not very familiar with this platform, and perhaps that is the main problem, but perhaps other readers will also be unfamiliar and I believe it needs more explanation. For example, does Fig. 4F indicate that there are no pathways predicted to be significantly upregulated by infection in the MDC population? This seems insconsistent with Fig4B and 4H, which show several Th1-related genes upregulated? IL1b downregulations is highlighted in the text, but IL-1a and IL-12 are both upregulated in the 4B scatter plot. Please clarify.

10) In Figure 5, 25 genes were shown to be differentially expressed by AM, RM, and MDC that were infected, compared to those that were uninfected. The authors then went on to validate protein expression for three of these genes using antibodies (Abca1, CD38, and CD14) and investigate infected cells expressing these 3 markers for the rest of the paper. However, it is not clear how these 3 markers were chosen from amongst the 25, as the expression levels of these 3 genes were relatively low compared to others. Were other validations also attempted? Or were these 3 just the best antibodies? Without an explanation the designation of Triple and double positive cells in the remainder of the manuscript seems somewhat arbitrary.

11) The importance of the BMDC experiments in Fig8A-B is unclear, even as stated by the authors themselves, and may not be needed in the manuscript. What do the CD38-negative cells represent? Are these cells that just haven’t fully differentiated in the in vitro culture? Is the left-hand plot in Fig8A the uninfected controls?

12) Do the authors have any insights about why, in Fig. 8D ABCA1 expression goes down with IFNg in vitro (unlike CD38 and CD14) even though it’s highly expressed in vivo?

13) Figure 7D depicts NOS2 expression by various myeloid populations based Boolean gating of the markers ABCA1, CD38, and CD14. A comparison of NOS2 staining in Mtb infected AM vs. MDC vs. RM would also be interested. The authors make conclusions about exposure of all of these myeloid populations to IFNg, but this conclusion is based on RNA-Seq of sorted bulk populations of infected cells. These populations may include subpopulations that were and were not exposed to IFNg. Assessing NOS2 at a single cell level would be informative, as the % positive may vary and this may mean some populations contain cells that are less exposed to IFNg than others. If so, the conclusions about the bulk population being exposed to T cells and IFNg should be softened, as there may be subpopulations, even perhaps large subpopulations that are not.

14) The authors use a YFP-expressing Mtb strain that was transformed using a plasmid that expresses YFP driven by a constitutive promoter. Usually plasmids are lost over time and at late timepoints most infected cells no longer express the plasmid and are fluorescent. Thus, the utility of these strains are usually restricted to the first few weeks of infection. In Figure 9 and 10 this strain is used to identify infected cells even 16 weeks post-infection. What percentage of the colonies continue to be fluorescent at each of these timepoints (3 weeks, 6 weeks, and 16 weeks)? (In Figure 10 there seems to be a much lower % of YFP+ cells at 10 weeks than at 6 weeks, whereas overall CFUs usually don’t drop in this timeframe, suggesting plasmid loss). Unless the authors can convincingly show that the plasmid is not preferentially lost in some cell types relative to other cell types (which may be true if the Mtb replication rate is different in different cell types), I suggest that the authors not show data at timepoints in which the % of infected cells that still express YFP is low, as it would be difficult to draw conclusions.

15) The conclusions on p16 regarding AM, and there highly activated state should be softened considerably. In this context, the work of Rothchild et al should be recognized which shows that AM are very slow to upregulate pro-inflammatory pathways during the first 10 days of infection. It should also be acknowledged that the conclusions from bulk RNA-Seq could mean that a subset of AM are activated by IFNg, whereas others subpopulations may not. This would need to be evaluated on a single cell level, preferentially in tissue sections to identify the relative locations of activated and unactivated cells.

Reviewer #3: No major revisions

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: (No Response)

Reviewer #2: 1. A lot of the FACS plots are missing percentage values inside the gates (for example, Fig 2C), which would be really helpful to interpreting the data. Also, in Figure 1H, should the AM percent say “85” instead of “12”?

2. The gating strategy shown in Fig S1 does not mention the “MDC” cells and instead only refers to them as CD11b DC. While you address this later on, it would be helpful for future figures if the MDC was mentioned there. Conversely, in Fig4H you again refer to CD11b DC instead of MDC.

3. The plots in Fig 4E-G should be labeled with the respective cell type for clarity.

4. Please include units for the Y-axis of Fig 4H. What do the bar heights represent? Are AM showing significantly stronger expression profiles for inflammatory genes compared to MDC? If so, this would conflict with Huang et al who find that IM (MDC) are more proinflammatory relative to AM.

5. Is IL-1b staining shown in Figure 7 is actually pro-IL1b. If so, please label it the plots and Methods accordingly.

6. Similar reporting of enriched NOS2 expression among Mtb-infected cells was reported in Huang et al and of enriched IL-1b in Cohen et al. Please acknowledge these when discussing Fig 7A. This activation status appears to be a general feature of Mtb-infected cells.

Reviewer #3: Minor revisions and thoughts:

Are Alveolar macrophages able to degrade the YFP protein more effectively than CD11chi MDC thus leaving unstained bacteria residing in these cells? Could an acid fast stain be done on these cells to determine they have lower numbers of bacteria.

Is there any evidence that CD11cHi MDC or equivalent cells exist in humans?

The authors describe the TP CD11cHi MDC having the highest level of NOS and IL-1beta which are normally associated with an increased bacillary killing. However Mtb seems to preferentially infect and reside in these cells how is this congruent ?

Alterations/Additions to figures.

Figure 1I. The first panel of this subsection examining Non PMN myeloid cells is a dot plot while the rest are contour plots.

Figure 4 Typo in legend of H

Figure 6 This figure lacks clarity specifically the A to H sub groups.

Figure 7 Same as figure 6

Figure 8D Statistics need to be applied to these data sets.

Figure 8E Collated MFI for ABCA1 between WT and KO should be graphed for figure 8E

Figure 10 Gates and numbers needed for this figure. Also the data should be collated and presented in this figure.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here on PLOS Biology: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see http://journals.plos.org/plospathogens/s/submission-guidelines#loc-materials-and-methods

Decision Letter 1

Marcel A Behr, Michael R Wessels

12 May 2020

Dear Dr. Behar,

We are pleased to inform you that your manuscript 'CD11cHi monocyte-derived macrophages are a major cellular compartment infected by Mycobacterium tuberculosis' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Marcel A. Behr

Associate Editor

PLOS Pathogens

Michael Wessels

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************************************************

Reviewer Comments (if any, and for reference):

Acceptance letter

Marcel A Behr, Michael R Wessels

10 Jun 2020

Dear Dr. Behar,

We are delighted to inform you that your manuscript, "CD11cHi monocyte-derived macrophages are a major cellular compartment infected by Mycobacterium tuberculosis," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Identification of 7 populations of myeloid cells in the lungs of Mtb-infected mice.

    CD11b and CD11c are frequently used to distinguish alveolar macrophages (AM) from pulmonary dendritic cells (DC): AM are generally CD11bloCD11chiMHCIIlow-int, while DC are CD11bint-hiCD11chiMHCIIhi. This strategy works well for uninfected mice housed under conventional conditions. However, during inflammation, AM upregulate both CD11c and MHCII. Therefore, the following scheme takes advantage of SiglecF to identify AM, independently of MHCII. Single cell suspensions obtained from the lungs of mice were gated based on (a) scatter, (b) singlets, and then dead cells excluded (c). Leukocytes in the lung were identified based on CD45 staining (d) and lymphoid cells were excluded by using a dump channel that consisted of anti-Thy1, CD19, and NK1.1 (e). Neutrophils (PMNs, “1”) were identified based on Ly6g expression (f). AM (“2”) were identified by their siglecFHiCD11cHi phenotype, while eosinophils (Eos, “3”) expressed lower amounts of SiglecF and no CD11c (i.e., siglecFintCD11c-) (g). CD11cintCD11bHi cells were identified as recruited macrophages (RM, “5”) and monocytes, and monocytes were further distinguished by their Ly6C expression (“4”). Finally, the remaining CD11cHi cells were designated as DC, and 2 different subsets identified by their expression of CD103 (i.e., CD103DC or cDC1, “6”) or CD11b (i.e., CD11bDC or cDC2, “7”). In the Mtb infected lung, siglecF-CD11cHiCD11bHi cells are likely to be a mixture of CD11bDC and CD11cHi MDC.

    (PDF)

    S2 Fig. A “Dump” strategy excludes lymphoid cells.

    In addition to eliminating debris, doublets, and dead cells from our analysis, an essential part of our strategy was to exclude lymphoid cells. After gating on CD45+ cells, lymphoid cells were identified by using a “dump” gate consisting of a mixture of antibodies specific for Thy1, CD19, and NK1.1 (a). Although these markers primarily identify lymphoid cells, some lymphoid cells are known to express low levels of CD11b, CD11c, and SiglecF, particularly when activated, which could lead to misclassification of cell types. Although there are few Dump+ cells that express CD11b, CD11c, or SiglecF in the lungs of uninfected mice (b, c), one sees a more complicated pattern of CD11b and CD11c expression by CD45+ cells by cells isolated from the lungs of Mtb-infected mice (S2b, left), by CD45+dump- cells (center), or by lymphoid cells (right). This strategy is even important when CD11b, CD11c, and SiglecF staining are used to identify lung myeloid cells (c). Thus, our staining panel and gating strategy identify seven major populations of distinct myeloid cells that are present in the lungs, independently of M. tuberculosis infection. This strategy facilitates accurate enumeration of myeloid cells and measurement of phenotypic changes during infection, independent of the markers used to identify the different cell populations. A possible confounder is whether activated myeloid cells express Thy1, CD19, or NK1.1 lineage markers. Analysis of Mtb-infected RAG knockout mice, which lack B and T cells but still have NK cells, shows that few if any activated cells (i.e., MHCII+) in the AM or MDC gate express the “dump markers” (d). As for the RM population, there were “Dump+” cells, which were presumably NK cells, but none in the MHCII+ region. The cells show up in the RM gate as they lack expression of the other markers used to identify distinct myeloid populations (i.e., they lack SiglecF, CD11c, Ly6c, and MHCII). Additionally, we determined the percentage of cells in the dump channel that were YFP+ (e). Cells in the myeloid gate were ~30 times more likely to be infected than cells in the dump gate (~4.2% vs 0.14%). Thus, the dump channel excludes very few infected cells from subsequent analysis.

    (PDF)

    S3 Fig. Identification of AM, CD103DC, and CD11bDC during Mtb infection.

    CD11b and CD11c can be used to discriminate AM and DC in uninfected mice; however, they need to be used in conjunction with other markers during Mtb infection. For example, in uninfected mice, CD11bloCD11chi cells are mostly AM (S3A Fig, left panel). Further analysis of the R1 gate shows that most of the cells are AM with some CD103DC (S3B Fig, top left panel). Similarly, CD11bhiCD11chi cells (S3A Fig, R2 gate) are nearly all CD11bDC (S3B Fig, bottom left panel). However, during Mtb infection, the pattern is more complex. The few CD11bloCD11chi cells (S3A Fig, R1 right panel) are a mixture of AM and DC (S3B Fig, R1), and the CD11bhiCD11chi cells are mostly CD11bDC and MDC but also AM (S3B Fig, R2). In contrast, using the gating scheme described above (S1 Fig), AM and eosinophils are unambiguously identified based on siglecF and CD11c, independently of infection (S3C Fig). The CD11chisiglecFlo cells define DC (Fig 3C, “DC gate”), while the CD11clow-intermsiglecFlo cells are RM and monocytes. The cells in the DC gate include both CD103DC and DC11bDC before infection, but after infection, CD11bDC dominate. As we discuss later, we think that although there are CD11bDC in this population, most of the cells are CD11chi monocyte-derived cells (CD11chi MDC).

    (PDF)

    S4 Fig. Gene expression analysis of YFP+ “CD11bDC” from the lungs of Mtb-infected mice reveals that they closely resemble CD11cHi MDC.

    A. Using well-described transcriptional gene signatures for AM, macrophages, DC and monocytes [2, 32], YFPpos AM, CD11cHi MDC, and RM were compared to well-defined lung myeloid cell populations from uninfected mice (data from www.Immgen.org) using a heat map with global normalization. The YFPpos AM have a transcriptional profile matching AM, while YFPpos CD11cHi MDC and resemble the monocyte/macrophage lineage. B. We developed a 21 gene signature (here, referred to as “ImmGen 1”) that distinguishes ImmGen DC from macrophages. An analysis using the expression of the 15 genes that are preferentially expressed in macrophages (top), the 6 genes that are preferentially expressed in DC (middle), or the combined 21 gene signature is quantified for 43 myeloid unique ImmGen myeloid cell populations, grouped by cell type. Red bar, median. pDC, plasmacytoid DC. Blue, ImmGen lung populations. C. The list of genes that make up the 21 gene signature.

    (PDF)

    S5 Fig. Infected cells display disproportionately high expression of Podoplanin.

    Lung cells were obtained from uninfected mice, or mice four weeks after aerosol infection with Rv.YFP. Podoplanin expression was analyzed by flow cytometry after gating on live CD45+ cells, excluding T cells, B cells, NK cells, and PMN. The black numbers are the percentage of events in each quadrant. The red numbers are the percentage of YFP-ve or YFP+ve events that express podoplanin.

    (PDF)

    S6 Fig. Distribution of Mtb among different cell types and expression of MHC II by infected cells late during infection.

    The H37Rv.YFP strain we use was transformed using a plasmid that expresses sfYFP driven by a constitutive promoter. These plasmids are lost over time and at late timepoints (≥16 wpi) most infected cells no longer express the plasmid based on the lack of fluorescence of CFU grown from lung homogenates. Thus, we cannot rule out that there was preferential plasmid loss in certain cell types or differential degradation of YFP. However, myeloid cells could still be detected at late time points up till 9 months after infection. The distribution of YFP among different cell types (A) and their expression of MHC II (B) 4 months after infection follows a similar trend as observed at 3 and 6 wpi (see Figs 9 and 10). However, because of the issue of plasmid loss, one must interpret these data cautiously.

    (PDF)

    Attachment

    Submitted filename: Point by point.docx

    Data Availability Statement

    All gene expression files are available from the GEO database (accession number: GSE146127). All other relevant data are within the manuscript and its supporting information files.


    Articles from PLoS Pathogens are provided here courtesy of PLOS

    RESOURCES